Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Priya Life Science Clinical trial register
Trackers› Clinical trials› Colorado
Clinical trial register · United States · industry-sponsored

Clinical Trials in Colorado, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9148 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 22 Nov 2026, 03:16 UTC
9148
Studies in scope
industry-sponsored, all four open statuses
4975
Recruiting now
open to new participants
2181
Lead sponsors
across recruiting studies
Top states
California 5328 Florida 4488 Illinois 2493 Georgia 2364 Arizona 2269
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca88 Janssen Research & Development, LLC71 Merck Sharp & Dohme LLC66 Eli Lilly and Company66 Novartis Pharmaceuticals56 AbbVie53 Hoffmann-La Roche53 Pfizer48 Bristol-Myers Squibb34 Sanofi29 GlaxoSmithKline26 Gilead Sciences24 Regeneron Pharmaceuticals23 Boehringer Ingelheim22 Novo Nordisk A/S20 Incyte Corporation20 Amgen20 Edwards Lifesciences17 Takeda15 Genentech, Inc.14 Bayer12 BeOne Medicines12 Abbott Medical Devices11 Boston Scientific Corporation11 Daiichi Sankyo10 Seagen, a wholly owned subsidiary of Pfizer10 Zimmer Biomet10 Alexion Pharmaceuticals, Inc.9 Vertex Pharmaceuticals Incorporated9 Genmab9 Immunovant Sciences GmbH8 Celgene8 Astellas Pharma Global Development, Inc.8 Biogen8 Jazz Pharmaceuticals8 BioMarin Pharmaceutical7 Ultragenyx Pharmaceutical Inc7 Juno Therapeutics, Inc., a Bristol-Myers Squibb Company7 Ipsen7 argenx7 Medtronic6 Medtronic Cardiovascular6 IDEAYA Biosciences6 BioNTech SE6 Cochlear6 Mirati Therapeutics Inc.6 4D Molecular Therapeutics6 ViiV Healthcare6 Ionis Pharmaceuticals, Inc.5 Kura Oncology, Inc.5 Revolution Medicines, Inc.5 Kumquat Biosciences Inc.5 Nurix Therapeutics, Inc.5 Exelixis5 Alkermes, Inc.5 Eikon Therapeutics5 Kite, A Gilead Company5 Mirum Pharmaceuticals, Inc.5 ModernaTX, Inc.5 Replimune, Inc.4 Aragon Pharmaceuticals, Inc.4 Olema Oncology, Inc.4 M.A. Med Alliance S.A.4 Alnylam Pharmaceuticals4 Summit Therapeutics4 Deciphera Pharmaceuticals, LLC4 Relay Therapeutics, Inc.4 Nuvalent Inc.4 W.L.Gore & Associates4 Madrigal Pharmaceuticals, Inc.4 EyePoint Pharmaceuticals, Inc.4 Vanda Pharmaceuticals4 QED Therapeutics, a BridgeBio company4 Vascutek Ltd.4 EyeBiotech Ltd.4 NS Pharma, Inc.4 Biohaven Therapeutics Ltd.4 TG Therapeutics, Inc.4 US Oncology Research4 UCB Biopharma SRL4 Adverum Biotechnologies, Inc.4 Philips Clinical & Medical Affairs Global4 PPD Development, LP4 Shockwave Medical, Inc.4 United Therapeutics4 Protara Therapeutics3 Loxo Oncology, Inc.3 Orca Biosystems, Inc.3 Longevity Metrics, Inc.3 Actelion3 Alkeus Pharmaceuticals, Inc.3 Supernus Pharmaceuticals, Inc.3 Tango Therapeutics, Inc.3 CSL Behring3 Kodiak Sciences Inc3 Akero Therapeutics, Inc3 Abiomed Inc.3 Eisai Inc.3 CG Oncology, Inc.3 Axsome Therapeutics, Inc.3 Genzyme, a Sanofi Company3 Shanghai Henlius Biotech3 Inhibrx Biosciences, Inc3 Otsuka Pharmaceutical Development & Commercialization, Inc.3 Biosense Webster, Inc.3 Liquidia Technologies, Inc.3 Candel Therapeutics, Inc.3 DePuy Orthopaedics3 Smith & Nephew, Inc.3 Sun Pharmaceutical Industries, Inc.3 Neurocrine Biosciences3 MediLink Therapeutics (Suzhou) Co., Ltd.3 TriGemX Bio, Inc.3 Viatris Innovation GmbH3 Natera, Inc.3 Criterium, Inc.3 Turning Point Therapeutics, Inc.3 Transcend Therapeutics3 Allogene Therapeutics3 Regenexx, LLC3 Intra-Cellular Therapies, Inc.3 Definium Therapeutics US, Inc.3 Stryker Trauma and Extremities3 Tenaya Therapeutics3 DBV Technologies3 Rhythm Pharmaceuticals, Inc.3 Karyopharm Therapeutics Inc3 SystImmune Inc.3 Xenon Pharmaceuticals Inc.3 BicycleTx Limited3 Annovis Bio Inc.3 Ono Pharmaceutical Co., Ltd.3 Sumitomo Pharma America, Inc.3 Ascendis Pharma Endocrinology Division A/S3 Harmony Biosciences Management, Inc.3 Longboard Pharmaceuticals3 Celldex Therapeutics3 Apellis Pharmaceuticals, Inc.3 Lyell Immunopharma, Inc.3 Crystalys Therapeutics3 Avidity Biosciences, Inc.3 Arthrex, Inc.2 Cerus Corporation2 NiKang Therapeutics, Inc.2 Sarepta Therapeutics, Inc.2 Calcilytix Therapeutics, Inc., a BridgeBio company2 Capricor Inc.2 Stemline Therapeutics, Inc.2 Editas Medicine, Inc.2 Insulet Corporation2 Agenus Inc.2 HemoCept Inc.2 Sebela Women's Health Inc.2 DualityBio Inc.2 USWM CT, LLC2 Medtronic Vascular2 Astria Therapeutics, Inc.2 NeuroDerm Ltd.2 Uromedica2 Edgewise Therapeutics, Inc.2 Cleerly, Inc.2 Teal Health, Inc.2 Exactech2 TORL Biotherapeutics, LLC2 Karuna Therapeutics, Inc., a Bristol Myers Squibb company2 Sonoma Biotherapeutics, Inc.2 Medicure2 Pharvaris Netherlands B.V.2 Occlutech International AB2 Jade Biosciences, Inc.2 AtriCure, Inc.2 Octapharma2 Acrivon Therapeutics2 Scholar Rock, Inc.2 PMV Pharmaceuticals, Inc2 Medtronic MiniMed, Inc.2 Artivion Inc.2 Alcon Research2 Cartesian Therapeutics2 Phathom Pharmaceuticals, Inc.2 Neurona Therapeutics2 Uniquity One (UNI)2 Puma Biotechnology, Inc.2 vTv Therapeutics2 Synergy Spine Solutions2 GIE Medical2 Poseida Therapeutics, Inc.2 Blueprint Medicines Corporation2 ArriVent BioPharma, Inc.2 Sapience Therapeutics2 InSilico Medicine Hong Kong Limited2 Corbus Pharmaceuticals Inc.2 Tela Bio Inc2 Avalyn Pharma Inc.2 Avenzo Therapeutics, Inc.2 Teva Branded Pharmaceutical Products R&D LLC2 MapLight Therapeutics2 C. R. Bard2 Vironexis Biotherapeutics Inc.2 Prevail Therapeutics2 BTL Industries Ltd.2 Treace Medical Concepts, Inc.2 Eidos Therapeutics, a BridgeBio company2 iECURE, Inc.2 3Spine2 Ocular Therapeutix, Inc.2 EMD Serono Research & Development Institute, Inc.2 Veradermics, Inc.2 ML Bio Solutions, Inc.2 Cytokinetics2 Priovant Therapeutics, Inc.2 Phanes Therapeutics2 Point Designs2 K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc2 Stryker Endoscopy2 Immunocore Ltd2 Alto Neuroscience2 Exact Sciences Corporation2 Quanta Therapeutics2 Stoke Therapeutics, Inc2 Akeso2 Cabaletta Bio2 Motiva USA LLC2 Viking Therapeutics, Inc.2 Medtronic Spinal and Biologics2 Tempus AI2 Glaukos Corporation2 Galderma R&D2 Op-T LLC2 Dizal Pharmaceuticals2 ACADIA Pharmaceuticals Inc.2 Acerta Pharma BV2 Splice Bio2 Verismo Therapeutics2 Arcus Biosciences, Inc.2 Cogent Biosciences, Inc.2 Corcept Therapeutics2 Autolus Limited2 Inspire Medical Systems, Inc.2 Nalu Medical, Inc.2 Fujifilm Pharmaceuticals U.S.A., Inc.2 Mediar Therapeutics2 H. Lundbeck A/S2 Pyxis Oncology, Inc2 Crinetics Pharmaceuticals Inc.2 Caribou Biosciences, Inc.2 Bolton Medical2 Erasca, Inc.2 Nkarta, Inc.2 Klein Buendel, Inc.2 TScan Therapeutics, Inc.2 GT Medical Technologies, Inc.2 Genprex, Inc.2 PROCEPT BioRobotics2 Immuneering Corporation2 Abivax S.A.2 MedImmune LLC2 Annexon, Inc.2 SeaStar Medical2 Curonix LLC2 Ferring Pharmaceuticals2 MicroPort Orthopedics Inc.2 Immatics US, Inc.2 CytomX Therapeutics2 McGuire Institute2 Iovance Biotherapeutics, Inc.2 Penumbra Inc.2 Intellia Therapeutics2 Verastem, Inc.2 Castle Creek Biosciences, LLC.2 Vima Therapeutics2 VIVEX Biologics, Inc.2 OncoC4, Inc.2 Accutar Biotechnology Inc2 Scancell Ltd1 Palvella Therapeutics, Inc.1 RHEACELL GmbH & Co. KG1 Aspen Neuroscience1 Airiver Medical, Inc.1 Eloxx Pharmaceuticals, Inc.1 Encoded Therapeutics1 Virta Health1 Mezzion Pharma Co. Ltd1 Vor Biopharma1 Axcynsis Therapeutics Pte Ltd1 Beam Therapeutics Inc.1 Appello Pharmaceuticals, Inc.1 Biotronik, Inc.1 Panafina, Inc.1 Amylyx Pharmaceuticals Inc.1 Nyxoah S.A.1 Optinose US Inc.1 ReGelTec, Inc.1 Mirador Therapeutics, Inc.1 Nammi Therapeutics Inc1 Crescent Biopharma, Inc.1 Mahzi Therapeutics1 MBX Biosciences1 Inherent Biosciences1 SymBio Pharmaceuticals1 Orchestra BioMed, Inc1 Shoulder Innovations1 Rise Therapeutics LLC1 Generate Biomedicines1 Massive Bio, Inc.1 CeraRoot SL1 BioInvent International AB1 CanariaBio Inc.1 Amplitude Vascular Systems, Inc.1 Normunity AccelCo, Inc.1 Duboce Biopharmaceuticals, Inc.1 Xeltis1 Agendia1 Zenith Epigenetics1 Mesoblast, Ltd.1 Multitude Therapeutics Inc.1 Spineart USA1 UroGen Pharma, Inc., a subsidiary of UroGen Pharma Ltd.1 HiberCell, Inc.1 Urotronic Inc.1 Akebia Therapeutics1 Renibus Therapeutics, Inc.1 Guardant Health, Inc.1 Vericel Corporation1 LISCure Biosciences1 CARsgen Therapeutics Co., Ltd.1 Avisi Technologies Inc.1 VarmX B.V.1 YolTech Therapeutics Co., Ltd1 Asahi Kasei Therapeutics, AB1 Soleno Therapeutics, Inc.1 OnKure, Inc.1 Berlin Heart, Inc1 Luna Diabetes1 Carcinex Inc1 Aura Biosciences1 Starlight Cardiovascular Inc1 Tizona Therapeutics, Inc1 Shanghai Allink Biotherapeutics Co., Ltd.1 Climb Bio, Inc.1 Vasomune Therapeutics, Inc.1 Anagram Therapeutics, Inc.1 Longeveron Inc.1 Rocket Pharmaceuticals Inc.1 Janssen Scientific Affairs, LLC1 Aerin Medical1 Medtronic Cardiac Surgery1 SeaSpine, Inc.1 Aurinia Pharmaceuticals Inc.1 Mabylon AG1 Vaxcyte, Inc.1 Quetzal Therapeutics1 Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany1 Helio Genomics1 Vifor Pharma, Inc.1 Altimmune, Inc.1 Cantex Pharmaceuticals1 Prilenia1 Healx Limited1 ADARx Pharmaceuticals, Inc.1 MacroGenics1 Curemark1 Halozyme Therapeutics1 Bolt Medical1 Serina Therapeutics1 phenox Inc.1 DynamiCure Biotechnology1 Aptevo Therapeutics1 Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)1 Nuvectis Pharma, Inc.1 ReAlta Life Sciences, Inc.1 REVA Medical, Inc.1 Kailera1 Barinthus Biotherapeutics1 Rigel Pharmaceuticals1 Medipost, Inc.1 Stelexis BioSciences1 Sutro Biopharma, Inc.1 Kedrion S.p.A.1 Medtronic Cardiac Rhythm and Heart Failure1 Tourmaline Bio, Inc., a Novartis Company1 VisionCare, Inc.1 Cytrellis Biosystems, Inc.1 Inventiva Pharma1 Italfarmaco1 Senseye, Inc.1 Immunome, Inc.1 Novelwise Pharmaceutical Corporation1 RAPT Therapeutics, Inc., a member of the GSK plc group of companies1 Corza Medical GmbH1 Spiro Medical, Inc.1 Pathos AI, Inc.1 Micro Medical Solution, Inc.1 V-Wave Ltd1 UniQure Biopharma B.V.1 Bicara Therapeutics1 Calluna Pharma AS1 GRIN Therapeutics, Inc.1 Ascendis Pharma Growth Disorders A/S1 ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)1 Aesculap Biologics, LLC1 OncoVerity, Inc.1 NMD Pharma A/S1 Zai Lab (Shanghai) Co., Ltd.1 Pharming Technologies B.V.1 Nocion Therapeutics1 Ensoma1 Pierre Fabre Medicament1 Bausch Health Americas, Inc.1 Step Pharma, SAS1 Cybin IRL Limited1 Gibson Institute of Cognitive Research1 Acorn Biolabs Inc.1 Limacorporate S.p.a1 Shanton Pharma Pte. Ltd.1 TrueBinding, Inc.1 Baxalta now part of Shire1 Digestive Care, Inc.1 Rivermark Medical1 7 Hills Pharma, LLC1 Parabilis Medicines, Inc.1 Endotronix, Inc.1 Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)1 CognifiSense Inc.1 Vergent Bioscience, Inc.1 Janssen Pharmaceutica N.V., Belgium1 Cellectis S.A.1 Blue Lake Biotechnology Inc.1 CNS Pharmaceuticals, Inc.1 Merz North America, Inc.1 Zynerba Pharmaceuticals, Inc.1 Adcendo ApS1 Mentor Worldwide, LLC1 Microvention-Terumo, Inc.1 Neuvosyn Laboratories, LLC1 Amal Therapeutics1 Epizyme, Inc.1 PreludeDx1 Areteia Therapeutics1 Vertanical GmbH1 Enveda Therapeutics1 Kartos Therapeutics, Inc.1 Conjupro Biotherapeutics, Inc.1 Servier Bio-Innovation LLC1 Paradigm Health1 MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals1 Priothera SAS1 AllRock Bio, Inc.1 ITM Solucin GmbH1 ProQR Therapeutics1 Humacyte, Inc.1 ONL Therapeutics1 Skyhawk Therapeutics, Inc.1 Abbisko Therapeutics Co, Ltd1 CardiacSense Ltd.1 Saluda Medical Pty Ltd1 Kahr Bio Australia Pty Ltd1 Saol Therapeutics Inc1 Ecotera Health LLC1 Spinal Kinetics1 Dogwood Therapeutics Inc.1 Allterum Therapeutics, Inc1 Okami Medical, Inc.1 Context Therapeutics Inc.1 Compass Therapeutics1 Guerbet1 Delfi Diagnostics Inc.1 bioAffinity Technologies Inc.1 Xentria, Inc.1 Protagonist Therapeutics, Inc.1 Providence Medical Technology, Inc.1 Happitech BV1 Daré Bioscience, Inc.1 Endospan Ltd.1 AskBio Inc1 Accent Therapeutics1 RasCal Therapeutics, Inc.1 BlueRock Therapeutics1 Dompé Farmaceutici S.p.A1 Praxis Precision Medicines1 OHB Pediatrics Ltd.1 Taiho Oncology, Inc.1 Orthofix Inc.1 pharmaand GmbH1 Kyverna Therapeutics1 Celcuity Inc1 Biodesix, Inc.1 Spyre Therapeutics, Inc.1 enGene, Inc.1 BiomX Ltd1 Nested Therapeutics, Inc1 Neuron23 Inc.1 Ascendis Pharma Bone Diseases A/S1 Impulse Dynamics1 SciTech Development, Inc.1 Insud Pharma1 Chugai Pharmaceutical1 Sequenom, Inc.1 Swedish Orphan Biovitrum1 Lumos Pharma1 Syndax Pharmaceuticals1 Koneksa Health1 Legacy Medical Consultants1 Nuvation Bio Inc.1 Anthos Therapeutics, Inc.1 Dren Bio1 Evommune, Inc.1 C4 Therapeutics, Inc.1 Cognito Therapeutics, Inc.1 Alimera Sciences1 CooperVision, Inc.1 Empirical Spine, Inc.1 Dimerix Bioscience Pty Ltd1 KalVista Pharmaceuticals, Ltd.1 ALX Oncology Inc.1 Medtronic Endovascular1 Acepodia Biotech, Inc.1 TransMedics1 Corxel Pharmaceuticals1 Biofrontera Inc.1 Sanofi Pasteur, a Sanofi Company1 GV20 Therapeutics1 Keri Medical SA1 AltruBio Inc.1 Janssen Biotech, Inc.1 Kahr Medical1 ImmunityBio, Inc.1 Miltenyi Biomedicine GmbH1 Biostar Pharma, Inc.1 SpliSense Ltd.1 N-Fold, LLC1 Kiniksa Pharmaceuticals International, plc1 Abbott Nutrition1 Apnimed1 Organon and Co1 Ethicon Endo-Surgery1 Satellos Bioscience, Inc.1 Alpine Immune Sciences Inc, A Subsidiary of Vertex1 ModeX Therapeutics, An OPKO Health Company1 Currax Pharmaceuticals1 Enliven Therapeutics1 Stealth BioTherapeutics Inc.1 NuVasive1 Rein Therapeutics1 REGENXBIO Inc.1 SI-BONE, Inc.1 Marker Therapeutics, Inc.1 Inari Medical1 CastleVax Inc.1 Expedition Therapeutics, Inc1 ALPFA Medical1 BioRestorative Therapies1 Minnesota HealthSolutions1 Biomed Industries, Inc.1 OSE Immunotherapeutics1 Chiesi Farmaceutici S.p.A.1 Biotheranostics, Inc.1 IlluminOss Medical, Inc.1 Elevara Medicines Limited1 Faron Pharmaceuticals Ltd1 Colospan Ltd.1 Iambic Therapeutics, Inc1 Biohaven Pharmaceuticals, Inc.1 Zhuhai Yufan Biotechnologies Co., Ltd1 iSTAR Medical1 Zogenix, Inc.1 CareDx1 AriBio Co., Ltd.1 Apollo Therapeutics Ltd1 Pulmonx Corporation1 Harbinger Health1 Alterome Therapeutics, Inc.1 Senseonics, Inc.1 Orphalan1 Aurion Biotech1 Nectero Medical, Inc.1 Lighthouse Pharmaceuticals, Inc.1 Adneuris Therapeutics, Inc.1 Inhibikase Therapeutics1 NervGen Pharma1 Avistone Biotechnology Co., Ltd.1 Moon Surgical1 Pulse Wave USA1 Oculis1 Cardiac Dimensions, Inc.1 Albireo, an Ipsen Company1 Ascentage Pharma Group Inc.1 Med-El Corporation1 Vaxart1 Vaxiion Therapeutics1 Stryker Instruments1 Infant Bacterial Therapeutics1 Elicio Therapeutics1 Sumitomo Pharma Switzerland GmbH1 Lucid Diagnostics, Inc.1 TuHURA Biosciences, Inc.1 Advenchen Laboratories, LLC1 Day One Biopharmaceuticals, Inc.1 Tectonic Therapeutic1 Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)1 Senti Biosciences1 Centessa Pharmaceuticals (UK) Limited1 William Brandenburg, MD1 SecondWave Systems Inc.1 SetPoint Medical Corporation1 Hutchmed1 Balmoral Medical company1 Kowa Research Institute, Inc.1 Clive Michelsen1 Tasca Therapeutics1 Neurocrine Switzerland GmbH1 Abeona Therapeutics, Inc1 Alpine Immune Sciences, Inc.1 Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)1 Orano Med LLC1 Spur Therapeutics1 PharmaMar1 Prelude Therapeutics Incorporated1 Mannkind Corporation1 Kymera Therapeutics, Inc.1 Sana Biotechnology1 Cortex1 Polyganics BV1 Aventix Medical Inc.1 Xoft, Inc.1 Cullinan Therapeutics Inc.1 R1 Therapeutics1 Agios Pharmaceuticals, Inc.1 IMMUNOe Research Centers1 Cerus Endovascular, Inc.1 Tulavi Therapeutics,Inc.1 Rivanna Medical, Inc.1 Tvardi Therapeutics, Incorporated1 Artios Pharma Ltd1 Sellas Life Sciences Group1 Xencor, Inc.1 Kardigan, Inc.1 Vega Therapeutics, Inc1 ReCor Medical, Inc.1 Ocusun Ophthalmic Pharmaceutical (Guangzhou) Co., Ltd.1 Imviva Bio1 Acrotech Biopharma Inc.1 Vogenx, Inc.1 Allotera Therapeutics1 TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)1 Tesaro, Inc.1 Syndeio Biosciences, Inc1 Medtronic Cardiac Ablation Solutions1 Kardion Inc1 Immunitas Therapeutics1 Woolsey Pharmaceuticals1 POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company1 Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA1 Aroa Biosurgery Limited1 ORIC Pharmaceuticals1 ShiraTronics1 Personalis Inc.1 DalCor Pharmaceuticals1 Ashibio Inc1 Miach Orthopaedics1 Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)1 Mabwell (Shanghai) Bioscience Co., Ltd.1 Actinogen Medical1 Upsher-Smith Laboratories1 Mineralys Therapeutics Inc.1 Target PharmaSolutions, Inc.1 March Biosciences Inc1 Emerald Clinical Inc.1 Aktiia SA1 CereGate Inc.1 GRAIL, Inc.1 D3 Bio (Wuxi) Co., Ltd1 Camurus AB1 CERo Therapeutics Holdings, Inc.1 TRIANA Biomedicines, Inc.1 Tetra Discovery Partners1 Centinel Spine1 Fin-Ceramica Faenza Spa1 Jacobio Pharmaceuticals Co., Ltd.1 Walden Biosciences1 GC Biopharma Corp1 Direct Biologics, LLC1 MBrace Therapeutics1 Sun Pharmaceutical Industries Limited1 Juno Therapeutics, a Subsidiary of Celgene1 atHeart Medical1 TeneoSeven, Inc.1 RayzeBio, Inc.1 ThalassaX Therapeutics United States Ltd1 Ascendis Pharma A/S1 Pheast Therapeutics1 DexCom, Inc.1 Dewpoint Therapeutics1 Flourish Science, Inc.1 Brainstorm-Cell Therapeutics1 SAb Biotherapeutics, Inc.1 Ceek Women's Health, INC1 Monte Rosa Therapeutics, Inc1 Savara Inc.1 Neurogene Inc.1 Renaissance Pharma Ltd.1 Seattle Project Corporation1 Viatris Inc.1 Renata Medical1 Kuros Biosurgery AG1 Starkey Laboratories, Inc1 CeraPedics, Inc1 Trevi Therapeutics1 Linnaeus Therapeutics, Inc.1 Rapport Therapeutics Inc.1 Medtronic Neurovascular Clinical Affairs1 Coherus Oncology, Inc.1 Greenwich LifeSciences, Inc.1 Cryosa, Inc.1 HeartFlow, Inc.1 Sitala Bio LTD1 Faeth Therapeutics1 Adient Medical1 Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)1 VectivBio AG1 Gyroscope Therapeutics Limited1 Dyne Therapeutics1 Disc Medicine, Inc1 Reunion Neuroscience Inc1 COUR Pharmaceutical Development Company, Inc.1 Otto Bock Healthcare Products GmbH1 Volastra Therapeutics, Inc.1 Zucara Therapeutics Inc.1 Kyowa Kirin Co., Ltd.1 soundBrilliance LLC1 Vicore Pharma AB1 Travere Therapeutics, Inc.1 Dendreon1 Baymatob Operations Pty Ltd1 Respicardia, Inc.1 Skribe Medical1 TWi Biotechnology, Inc.1 Axogen Corporation1 Urovant Sciences GmbH1 Simcha IL-18, Inc.1 Astellas Pharma Inc1 Tyra Biosciences, Inc1 ReCode Therapeutics1 ENTire Medical Ltd.1 CarThera1 ABL Bio, Inc.1 RTI Surgical1 ONWARD Medical, Inc.1 I-Mab Biopharma US Limited1 Neurotech Pharmaceuticals1 Tolmar Inc.1 Ardelyx1 ZimVie1 Alebund Pharmaceuticals1 Zydus Therapeutics Inc.1 SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany1 Aminex Therapeutics, Inc.1 Cerevance1 Lipocine Inc.1 JC Medical, Inc., an affiliate of Edwards Lifesciences LLC1 OnCusp Therapeutics, Inc.1 Allurion Technologies1 Novartis Gene Therapies1
Target enrolment
to

Trials with a site in Colorado

2073 of 9148 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Recruiting
Mabwell (Shanghai) Bioscience Co., Ltd.
Phase 1
52
California, Colorado, Illinois, Massachusetts, New York, Tennessee
2025-08-11
Recruiting
ACADIA Pharmaceuticals Inc.
Phase 2
180
California, Colorado, District of Columbia, Florida, Hawaii, Illinois, Kansas, New York
2025-08-06
Recruiting
AstraZeneca
Phase 3
700
Arizona, California, Colorado, Florida, Georgia, Illinois, Indiana, Maryland
2025-08-06
Recruiting
Sanofi
Phase 3
723
Arizona, California, Colorado, Connecticut, Florida, Georgia, Idaho, Kentucky
2025-08-06
Recruiting
A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma
NCT06624644Melanoma (Skin Cancer), Melanoma Stage IIIB-IV, Cutaneous Melanoma, Unresectable Melanoma
Linnaeus Therapeutics, Inc.
Phase 2/3
135
California, Colorado, Florida, Massachusetts, New Mexico, Pennsylvania
2025-08-06
Active, closed
Baymatob Operations Pty Ltd
Not applicable
1,000
Colorado, Louisiana, New York, Ohio, Pennsylvania
2025-08-06
Recruiting
Sun Pharmaceutical Industries, Inc.
Phase 3
355
Alabama, Arizona, Arkansas, California, Colorado, Florida, Georgia, Idaho
2025-08-05
Recruiting
Crystalys Therapeutics
Phase 3
250
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Indiana
2025-08-04
Recruiting
Rise Therapeutics LLC
Phase 1
33
Colorado, Tennessee
2025-08-01
Recruiting
A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors
NCT06997029Advanced Solid Tumor, Advanced Breast Cancer, Advanced Ovarian Cancer
Bristol-Myers Squibb
Phase 1
234
Alabama, California, Colorado, Massachusetts, Missouri, New Hampshire, New York, Texas
2025-08-01
Recruiting
Crystalys Therapeutics
Phase 3
500
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Indiana
2025-08-01
Active, closed
Pfizer
Phase 3
208
California, Colorado, District of Columbia, Florida, Illinois, Indiana, Maryland, Michigan
2025-07-31
Recruiting
Inspire Medical Systems, Inc.
Observational
70
Colorado, Florida, Illinois, Kansas, New York
2025-07-31
Recruiting
AstraZeneca
Phase 1
40
Arizona, California, Colorado, Florida, Georgia, Iowa, Minnesota, Missouri
2025-07-31
Recruiting
Kodiak Sciences Inc
Phase 3
600
Arizona, California, Colorado, Connecticut, Florida, Illinois, Indiana, Maryland
2025-07-30
Recruiting
AbbVie
Phase 2
377
California, Colorado, Minnesota, New Jersey, New York, Ohio, Oklahoma, Oregon
2025-07-30
Active, closed
Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects With Solid Tumors
NCT07021066Gastric Adenocarcinoma, Advanced Pancreatic Ductal Adenocarcinoma, Esophageal Adenocarcinoma, Biliary Tract Cancer
SystImmune Inc.
Phase 1
160
Arizona, California, Colorado, Connecticut, Louisiana, Michigan, New Jersey, Tennessee
2025-07-30
Recruiting
Reunion Neuroscience Inc
Phase 2
100
Alabama, Arizona, California, Colorado, Florida, Georgia, Hawaii, Illinois
2025-07-30
Recruiting
Optinose US Inc.
Phase 3
84
Alabama, Arizona, California, Colorado, Georgia, Illinois, Kentucky, Maryland
2025-07-28
Recruiting
Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy.
NCT06858319Kidney Diseases, Kidney Diseases, Chronic, Urological Diseases, Glomerulonephritis
Novartis Pharmaceuticals
Phase 3
220
Colorado, Florida, Iowa, New York, Tennessee, Texas
2025-07-28
Active, closed
Safety and Efficacy of VDPHL01 in Females With Androgenetic Alopecia (AGA)
NCT07146022Androgenetic Alopecia (AGA), Androgenetic Alopecia, AGA, Female Androgenetic Alopecia
Veradermics, Inc.
Phase 3
552
Alabama, Arizona, Arkansas, California, Colorado, Florida, Georgia, Idaho
2025-07-25
Recruiting
Kiniksa Pharmaceuticals International, plc
Phase 2/3
325
Arizona, California, Colorado, District of Columbia, Florida, Georgia, Illinois, Indiana
2025-07-25
Recruiting
A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
NCT07066657Locally Advanced or Metastatic Solid Tumors, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer
DrugMRG007
ArriVent BioPharma, Inc.
Phase 1
572
California, Colorado, Florida, Tennessee, Texas, Virginia, Washington
2025-07-25
Recruiting
Tela Bio Inc
Not applicable
173
Alabama, Colorado, Kentucky, North Carolina, Texas
2025-07-25
Recruiting
Abeona Therapeutics, Inc
Observational
250
California, Colorado, Illinois, Texas
2025-07-25
Recruiting
Celcuity Inc
Phase 3
1,180
Arkansas, California, Colorado, Florida, Kansas, Kentucky, Maryland, Massachusetts
2025-07-24
Recruiting
Tempus AI
Not applicable
900
Alabama, Arizona, Arkansas, California, Colorado, Florida, Illinois, Indiana
2025-07-23
Recruiting
Pfizer
Phase 3
714
Alaska, California, Colorado, District of Columbia, Florida, Illinois, Kansas, Maine
2025-07-23
Recruiting
Sonoma Biotherapeutics, Inc.
Observational
36
California, Colorado, Illinois, Massachusetts, Minnesota, North Carolina, Texas
2025-07-22
Recruiting
Boehringer Ingelheim
Phase 3
11,800
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Hawaii
2025-07-22
Recruiting
4D Molecular Therapeutics
Phase 3
480
Arizona, California, Colorado, Florida, Georgia, Illinois, Indiana, Louisiana
2025-07-22
Recruiting
Bristol-Myers Squibb
Phase 3
586
California, Colorado, Florida, Illinois, Indiana, Massachusetts, Michigan, Mississippi
2025-07-21
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,000
Alabama, Arizona, California, Colorado, Delaware, Florida, Kentucky, Nevada
2025-07-21
Recruiting
DualityBio Inc.
Phase 2
750
California, Colorado, Florida, Georgia, Maryland, Nebraska, New York, Oregon
2025-07-18
By invitation
Cybin IRL Limited
Phase 3
468
Arizona, California, Colorado, Florida, Georgia, Illinois, Maryland, Massachusetts
2025-07-18
Recruiting
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
NCT06765109Non-small Cell Lung Cancer, Anaplastic Lymphoma Kinase-positive
Nuvalent Inc.
Phase 3
450
Arizona, California, Colorado, Florida, Georgia, Massachusetts, Michigan, Missouri
2025-07-17
Recruiting
Kodiak Sciences Inc
Phase 3
300
Arizona, California, Colorado, Connecticut, Florida, Illinois, Indiana, Maryland
2025-07-16
Recruiting
Bristol-Myers Squibb
Phase 3
426
Arizona, California, Colorado, Connecticut, Florida, Georgia, Massachusetts, Michigan
2025-07-16
Recruiting
A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases
NCT06570798Systemic Lupus Erythematosus, Active Refractory Rheumatoid Arthritis
Amgen
Phase 2
220
Arizona, Colorado, Florida, Louisiana, Massachusetts, Minnesota, New York, Ohio
2025-07-16
Recruiting
Merck Sharp & Dohme LLC
Phase 3
477
Arizona, California, Colorado, Florida, Georgia, Idaho, Illinois, Indiana
2025-07-16
Recruiting
Continuation Study With Oral MC-1 for Treatment of Patients With PNPO-Deficiency
NCT07928388Pyridox(am)Ine 5'-Phosphate Oxidase Deficiency
Medicure
Phase 3
10
California, Colorado, Massachusetts
2025-07-15
Recruiting
Pfizer
Phase 3
300
California, Colorado, District of Columbia, Florida, Georgia, Idaho, Illinois, Maryland
2025-07-14
Active, closed
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 2
89
Arizona, California, Colorado, Florida, Georgia, Indiana, Louisiana, Massachusetts
2025-07-14
Recruiting
Biostar Pharma, Inc.
Phase 2
120
California, Colorado, Georgia, Illinois, Maryland, Nevada, New York, Texas
2025-07-14
Recruiting
Bristol-Myers Squibb
Phase 3
586
California, Colorado, District of Columbia, Florida, Georgia, Illinois, Massachusetts, Minnesota
2025-07-14
Recruiting
Galderma R&D
Observational
1,000
Alabama, Arizona, California, Colorado, Connecticut, Florida, Illinois, Indiana
2025-07-14
Active, closed
Novartis Pharmaceuticals
Phase 3
409
Alabama, Arizona, Arkansas, California, Colorado, District of Columbia, Florida, Georgia
2025-07-11
Active, closed
Harbinger Health
Observational
2,450
California, Colorado, Florida, Georgia, Illinois, Iowa, Kansas, Louisiana
2025-07-11
Recruiting
Bristol-Myers Squibb
Phase 3
426
Arizona, California, Colorado, Florida, Louisiana, Maryland, Massachusetts, Michigan
2025-07-10
Active, closed
Novartis Pharmaceuticals
Phase 2
168
California, Colorado, Connecticut, Florida, Georgia, Illinois, Massachusetts, Michigan
2025-07-07
By invitation
Starkey Laboratories, Inc
Not applicable
100
Colorado
2025-07-07
Active, closed
Novartis Pharmaceuticals
Phase 2
138
California, Colorado, Connecticut, Indiana, Massachusetts, Nebraska, New York, Pennsylvania
2025-07-03
Recruiting
Alnylam Pharmaceuticals
Phase 3
2,250
California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Illinois, Indiana
2025-07-02
Recruiting
Study With Phage for CF Subjects With Pseudomonas Lung Infection
NCT06998043Chronic Pseudomonas Aeruginosa Infection, Cystic Fibrosis (CF)
BiomX Ltd
Phase 2
63
Alabama, Alaska, Arkansas, California, Colorado, Florida, New Jersey, New York
2025-07-02
Recruiting
Novartis Pharmaceuticals
Phase 3
940
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Iowa
2025-07-01
Active, closed
Immunovant Sciences GmbH
Phase 2
180
California, Colorado, Florida, Illinois, Louisiana, New York, Pennsylvania, Tennessee
2025-06-30
Not yet open
Brainstorm-Cell Therapeutics
Phase 3
200
Arizona, California, Colorado, Florida, Illinois, Massachusetts, Minnesota, Oregon
2025-06-30
Recruiting
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
NCT06966700Breast Neoplasms, Triple Negative Breast Neoplasms, HR Low-Positive/HER2-Negative Breast Neoplasms
Merck Sharp & Dohme LLC
Phase 3
2,400
Arizona, California, Colorado, Florida, Georgia, Illinois, Indiana, Louisiana
2025-06-30
Active, closed
Pfizer
Phase 1/2
74
Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Oregon
2025-06-30
Recruiting
AstraZeneca
Phase 2
987
Alabama, Arizona, California, Colorado, Florida, Georgia, Iowa, Kentucky
2025-06-27
Recruiting
Novo Nordisk A/S
Phase 2
200
Alabama, Arizona, California, Colorado, Florida, Kentucky, Michigan, Minnesota
2025-06-27
Recruiting
A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease
NCT07113522Inflammatory Bowel Disease (IBD), Ulcerative Colitis (UC), Crohn's Disease
DrugMT-201
Mirador Therapeutics, Inc.
Phase 2
140
Alabama, Arizona, Arkansas, Colorado, Florida, Georgia, Illinois, Louisiana
2025-06-26
By invitation
Global Open-Label Extension Study of Del-desiran for the Treatment of DM1
NCT07008469Myotonic Dystrophy Type 1, DM1, Myotonic Dystrophy, Myotonia
Avidity Biosciences, Inc.
Phase 3
199
California, Colorado, Florida, Indiana, Kansas, Maryland, Massachusetts, Minnesota
2025-06-26
Recruiting
Regeneron Pharmaceuticals
Phase 3
2,000
Alabama, California, Colorado, Florida, Maryland, Massachusetts, New Jersey, North Carolina
2025-06-25
Active, closed
DBV Technologies
Phase 3
480
Alabama, Arizona, Arkansas, California, Colorado, District of Columbia, Florida, Georgia
2025-06-24
Recruiting
Kumquat Biosciences Inc.
Phase 1
84
Arizona, California, Colorado, Connecticut, Florida, Iowa, Minnesota, Ohio
2025-06-24
Active, closed
VK2735 for Weight Management Phase 3
NCT07104500Weight Loss
DrugVK2735
Viking Therapeutics, Inc.
Phase 3
4,500
Alabama, Arizona, Arkansas, California, Colorado, District of Columbia, Florida, Georgia
2025-06-23
Active, closed
Viking Therapeutics, Inc.
Phase 3
1,100
Alabama, Arizona, Arkansas, California, Colorado, Florida, Georgia, Hawaii
2025-06-23
Active, closed
Incyte Corporation
Phase 3
580
Arizona, Arkansas, California, Colorado, Florida, Georgia, Illinois, Indiana
2025-06-23
Recruiting
GlaxoSmithKline
Phase 3
961
Alabama, Colorado, Florida, Georgia, Idaho, Illinois, Louisiana, Maine
2025-06-23
Recruiting
Apellis Pharmaceuticals, Inc.
Phase 2
240
Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois, Indiana
2025-06-23
Recruiting
JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort A: Vilobelimab
NCT06701682Acute Respiratory Distress Syndrome (ARDS), ARDS, ARDS (Acute Respiratory Distress Syndrome), Acute Respiratory Distress Syndrome
PPD Development, LP
Phase 2
200
Alabama, California, Colorado, District of Columbia, Florida, Idaho, Illinois, Massachusetts
2025-06-21
Recruiting
AbbVie
Phase 2
180
Arizona, Arkansas, California, Colorado, Florida, Illinois, Louisiana, Michigan
2025-06-20
Active, closed
Calluna Pharma AS
Phase 2
150
California, Colorado, Florida, Kansas, North Carolina, Ohio, Pennsylvania, Utah
2025-06-20
Recruiting
Immunovant Sciences GmbH
Phase 2
210
Arizona, California, Colorado, Florida, Georgia, Kansas, Kentucky, Missouri
2025-06-19
Recruiting
To Assess the Utility of the Point Mini in a Clinical Take-home Study
NCT06501092Amputation; Traumatic, Hand, Amputation, Congenital
Point Designs
Not applicable
14
Colorado, Georgia
2025-06-18
Active, closed
Incyte Corporation
Phase 3
159
Alabama, Arizona, Colorado, Florida, Georgia, Idaho, Illinois, Maryland
2025-06-17
Recruiting
BlueRock Therapeutics
Phase 3
102
Arizona, Arkansas, California, Colorado, District of Columbia, Florida, Illinois, Kansas
2025-06-17
Active, closed
An Observational Study of Individuals With Isolated Dystonia
NCT07111663Isolated/Primary Dystonia That Affects More Than One Region of the Body
Vima Therapeutics
Observational
200
Arizona, California, Colorado, Florida, Georgia, Illinois, Maryland, Michigan
2025-06-17
Recruiting
Study of Ravulizumab in Pediatric Participants With Primary IgAN
NCT07024563IgAN, IgAVN, Immunoglobulin A Nephropathy, Immunoglobulin A Vasculitis Associated Nephritis
Alexion Pharmaceuticals, Inc.
Phase 3
36
California, Colorado
2025-06-14
Recruiting
Relay Therapeutics, Inc.
Phase 2
277
Arizona, Arkansas, California, Colorado, Georgia, Indiana, Iowa, Maryland
2025-06-13
Recruiting
A Study of a Novel Iron-based Phosphate Binder AP301 in Patients With Hyperphosphatemia in the U.S. and China
NCT06933472Hyperphosphatemia, Chronic Kidney Disease, Receiving Dialysis, ESRD (End-Stage Renal Disease), Dialysis
Alebund Pharmaceuticals
Phase 3
264
California, Colorado, Connecticut, Florida, Georgia, Louisiana, Mississippi, New Mexico
2025-06-13
Active, closed
Incyte Corporation
Phase 3
573
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois
2025-06-12
Recruiting
GlaxoSmithKline
Phase 1/2
85
Arizona, Colorado, Connecticut, Minnesota, New Jersey, Tennessee
2025-06-12
Recruiting
Glaukos Corporation
Phase 2
110
Colorado, Oklahoma, Texas
2025-06-12
Recruiting
GlaxoSmithKline
Phase 1/2
346
California, Colorado, New York, North Carolina, Texas, Washington, Wisconsin
2025-06-11
Recruiting
BioNTech SE
Phase 3
480
California, Colorado, Connecticut, District of Columbia, Florida, Illinois, Kentucky, Louisiana
2025-06-10
Active, closed
Ionis Pharmaceuticals, Inc.
Phase 3
156
California, Colorado, District of Columbia, Florida, Georgia, Illinois, Massachusetts, Missouri
2025-06-10
Recruiting
JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort B: Paridiprubart
NCT06701669Acute Respiratory Distress Syndrome (ARDS), ARDS, ARDS (Acute Respiratory Distress Syndrome), Acute Respiratory Distress Syndrome
PPD Development, LP
Phase 2
200
Alabama, California, Colorado, District of Columbia, Florida, Idaho, Illinois, Massachusetts
2025-06-10
Recruiting
JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS (Master Record)
NCT06703073Acute Respiratory Distress Syndrome (ARDS), ARDS, ARDS (Acute Respiratory Distress Syndrome), Acute Respiratory Distress Syndrome
PPD Development, LP
Phase 2
600
Alabama, California, Colorado, District of Columbia, Florida, Idaho, Illinois, Massachusetts
2025-06-10
Recruiting
A Study to Evaluate Del-brax (Also Referred to as AOC 1020) in Participants With FSHD
NCT07038200Facioscapulohumeral Muscular Dystrophy, FSHD, FSHD - Facioscapulohumeral Muscular Dystrophy, FSHD1
Avidity Biosciences, Inc.
Phase 3
200
California, Colorado, Florida, Iowa, Kansas, Maryland, Massachusetts, New York
2025-06-10
Recruiting
Celgene
Phase 2
120
Alabama, Arizona, California, Colorado, District of Columbia, Florida, Georgia, Hawaii
2025-06-09
Recruiting
Boehringer Ingelheim
Phase 3
1,755
Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2025-06-09
Recruiting
Celgene
Phase 2
200
Alabama, Arizona, Colorado, Florida, Kansas, Massachusetts, Michigan, Missouri
2025-06-05
Recruiting
First-in-Human Study of ADCE-D01 in Soft Tissue Sarcoma
NCT06797999Metastatic Soft Tissue Sarcoma, Unresectable Soft Tissue Sarcoma
Adcendo ApS
Phase 1/2
270
Colorado, Florida, New York, Texas
2025-06-05
Recruiting
Boehringer Ingelheim
Phase 2
300
Arizona, California, Colorado, Connecticut, Florida, Georgia, Indiana, Kansas
2025-06-05
Recruiting
Erasca, Inc.
Phase 1
600
California, Colorado, Florida, Georgia, Massachusetts, New York, Texas, Virginia
2025-06-05
Recruiting
Janssen Research & Development, LLC
Phase 3
600
Alabama, Arizona, Arkansas, California, Colorado, Delaware, Florida, Illinois
2025-06-04
Recruiting
Avenzo Therapeutics, Inc.
Phase 1/2
480
Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Massachusetts
2025-06-04
Recruiting
AstraZeneca
Phase 3
15,100
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, Florida
2025-06-04
Active, closed
Stoke Therapeutics, Inc
Phase 3
170
Arizona, Arkansas, California, Colorado, District of Columbia, Florida, Illinois, Massachusetts
2025-06-04
Recruiting
Sanofi
Phase 2
99
Alabama, Arizona, California, Colorado, Florida, Georgia, Iowa, Kansas
2025-06-03
Recruiting
A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
NCT06999187Triple Negative Breast Cancer, HER2-negative Breast Cancer, Non Small Cell Lung Cancer, Cervical Cancer
Dren Bio
Phase 1
96
Colorado, Florida, North Carolina, Oklahoma, South Carolina, Texas, Virginia
2025-06-03
Active, closed
Boston Scientific Corporation
Not applicable
376
Alabama, Arkansas, California, Colorado, Florida, Georgia, Idaho, Illinois
2025-06-03
Active, closed
Virtual Reality Treatment for Adults With Chronic Back Pain (VRNT)
NCT07033195Chronic Pain, Chronic Back Pain, Chronic Lower Back Pain (CLBP)
CognifiSense Inc.
Not applicable
200
Colorado
2025-06-01
Recruiting
Tango Therapeutics, Inc.
Phase 1/2
183
Arizona, Colorado, District of Columbia, Florida, Illinois, Indiana, Iowa, Massachusetts
2025-05-31
Recruiting
Neurocrine Biosciences
Phase 3
200
California, Colorado, Connecticut, Florida, Illinois, Maryland, Nevada, New Jersey
2025-05-30
Recruiting
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
NCT06533579B-cell Acute Lymphoblastic Leukemia, Large B-cell Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Vironexis Biotherapeutics Inc.
Phase 1/2
32
California, Colorado, Florida, Minnesota, New York, North Carolina, Ohio, Oregon
2025-05-30
Recruiting
Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET
NCT06784752Somatostatin Receptor Positive (SSTR+), Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)
Novartis Pharmaceuticals
Phase 3
240
Arizona, Arkansas, Colorado, Connecticut, Florida, Georgia, Kentucky, Louisiana
2025-05-30
Active, closed
Eli Lilly and Company
Phase 3
586
Arizona, California, Colorado, Florida, Kansas, Louisiana, Massachusetts, Michigan
2025-05-29
Recruiting
Biohaven Therapeutics Ltd.
Phase 2/3
550
Alabama, Arizona, California, Colorado, Connecticut, Florida, Illinois, Kansas
2025-05-28
Recruiting
Immunovant Sciences GmbH
Phase 3
231
Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2025-05-27
Recruiting
A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis
NCT07012395Ulcerative Colitis, Inflammatory Bowel Diseases, Colitis, Colitis, Ulcerative
Spyre Therapeutics, Inc.
Phase 2
645
California, Colorado, Florida, Illinois, Kansas, Kentucky, Louisiana, Maryland
2025-05-27
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
50
California, Colorado, Connecticut, Florida, Iowa, Massachusetts, Michigan, Missouri
2025-05-26
Recruiting
Eikon Therapeutics
Phase 2/3
740
Arizona, Arkansas, California, Colorado, Delaware, Florida, Maryland, Missouri
2025-05-22
Active, closed
Alkermes, Inc.
Phase 2
126
Alabama, Arizona, Arkansas, California, Colorado, Florida, Georgia, Illinois
2025-05-22
Recruiting
Minima Stent System Post- Approval Study (PAS)
NCT06828770Pulmonary Artery Stenosis, Aortic Coarctation
Renata Medical
Observational
100
California, Colorado, Florida, Georgia, Illinois, Indiana, Massachusetts, Michigan
2025-05-21
Recruiting
Pfizer
Phase 2
252
Alabama, Arizona, California, Colorado, Georgia, Illinois, Kansas, Michigan
2025-05-20
Recruiting
DB-3Q bmMSC-EVs in Patients With Perianal Fistulizing Crohn's Disease
NCT06918808Perianal Fistula Due to Crohn's Disease
DrugDB-3Q
Direct Biologics, LLC
Phase 2
36
Colorado, Missouri, New York, Pennsylvania, Tennessee
2025-05-19
Recruiting
Penumbra Inc.
Observational
300
Arizona, California, Colorado, Connecticut, Delaware, Florida, Georgia, Illinois
2025-05-18
Recruiting
Corxel Pharmaceuticals
Phase 2/3
740
California, Colorado, District of Columbia, Florida, Illinois, Kansas, Maryland, Michigan
2025-05-15
Active, closed
Ashibio Inc
Phase 1/2
10
Colorado
2025-05-14
Active, closed
RADIQAL Study (Radiation Dose and Image Quality Trial)
NCT06944509Coronary Artery Disease
Philips Clinical & Medical Affairs Global
Not applicable
824
Colorado, Georgia, New York
2025-05-14
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,440
Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Illinois
2025-05-13
Active, closed
Merck Sharp & Dohme LLC
Phase 2
130
Colorado, Kansas, New Mexico
2025-05-12
Recruiting
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
NCT06563895Amyloidosis, Amyloid Cardiomyopathy, Transthyretin Amyloidosis, Cardiomyopathies
Eidos Therapeutics, a BridgeBio company
Phase 3
587
California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Illinois, Maryland
2025-05-12
Active, closed
Eli Lilly and Company
Phase 3
465
California, Colorado, Florida, Iowa, Minnesota, Missouri, Nevada, North Carolina
2025-05-12
Recruiting
Hoffmann-La Roche
Phase 3
425
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Kansas
2025-05-12
Recruiting
CNP-103 in Adolescent and Adult Subjects Ages 12-35 With Recently Diagnosed (Within 6 Months) Stage 3 Type 1 Diabetes (T1D)
NCT06783309Type 1 Diabetes Mellitus, T1D, T1DM, T1DM - Type 1 Diabetes Mellitus
COUR Pharmaceutical Development Company, Inc.
Phase 1/2
72
Arizona, California, Colorado, Florida, Georgia, Idaho, Illinois, Indiana
2025-05-12
Recruiting
Onyx™ Liquid Embolic IDE Clinical Study
NCT06742801Peripheral Arterial Hemorrhage, Trauma, GI Bleed, Ulcer
Medtronic Endovascular
Not applicable
119
Arizona, California, Colorado, Connecticut, Illinois, Iowa, Massachusetts, Nebraska
2025-05-09
Recruiting
Pfizer
Phase 4
100
Arizona, California, Colorado, Florida, Georgia, Illinois, Indiana, Kentucky
2025-05-07
Recruiting
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
NCT06881784NSCLC (Non-small Cell Lung Cancer), Non-Small Cell Lung Cancer, NSCLC, NSCLC (Non-small Cell Lung Carcinoma)
Revolution Medicines, Inc.
Phase 3
590
Alabama, California, Colorado, Connecticut, Florida, Georgia, Illinois, Indiana
2025-05-06
Recruiting
AstraZeneca
Phase 3
1,220
Arizona, California, Colorado, Connecticut, Delaware, Florida, Georgia, Hawaii
2025-05-06
Active, closed
Cartesian Therapeutics
Phase 3
128
Arizona, California, Colorado, District of Columbia, Florida, Illinois, Kansas, Kentucky
2025-05-06
Recruiting
Takeda
Phase 2
88
Alabama, Arizona, California, Colorado, Florida, Georgia, Maryland, Michigan
2025-05-06
Recruiting
Long-term Follow-up of a Cochlear Implant With Dexamethasone Eluting Electrode Array
NCT06936449Sensorineural Hearing Loss, Bilateral Hearing Loss
Cochlear
Observational
19
Colorado, Iowa, Ohio
2025-05-05
Active, closed
Vanda Pharmaceuticals
Phase 2
50
California, Colorado, Minnesota, Texas, Virginia
2025-05-05
Active, closed
Mediar Therapeutics
Phase 2
168
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Kansas
2025-05-05
Recruiting
BioNTech SE
Phase 1/2
594
Arizona, California, Colorado, Florida, Iowa, Minnesota, New Jersey, New York
2025-05-02
Recruiting
Motiva Implants® Post-Approval Study
NCT06938399Breast Implant
Motiva USA LLC
Not applicable
2,400
California, Colorado, District of Columbia, Florida, Illinois, Kentucky, Louisiana, Maryland
2025-05-01
Recruiting
Eikon Therapeutics
Phase 1/2
130
Colorado, Florida, Massachusetts, Texas, Virginia
2025-04-30
Active, closed
Avexitide for Treatment of Post-Bariatric Hypoglycemia
NCT06747468Post Bariatric Hypoglycemia
Amylyx Pharmaceuticals Inc.
Phase 3
75
California, Colorado, Florida, Georgia, Kansas, Massachusetts, New York, North Carolina
2025-04-29
Recruiting
HemoCept Inc.
Observational
20
Colorado
2025-04-29
Recruiting
Stelexis BioSciences
Phase 1
105
California, Colorado, Florida, Massachusetts, Missouri, New York, Ohio, Texas
2025-04-28
Recruiting
Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors
NCT07080242Small Cell Lung Cancer Metastatic or Locally Advanced, Neuroendocrine Cancer, Metastatic Neuroendocrine Prostate Cancer, Metastatic Advanced Poorly Differentiated Gastroenteropancreatic Neuroendocrine Carcinoma
SystImmune Inc.
Phase 1
120
Alabama, California, Colorado, Connecticut, Georgia, Louisiana, New Jersey, New York
2025-04-28
Recruiting
Study of ISM3412 in Participants With Locally Advanced/Metastatic Solid Tumors
NCT06414460Locally Advanced/Metastatic Solid Tumors
InSilico Medicine Hong Kong Limited
Phase 1/2
146
Colorado, Connecticut, Indiana, Tennessee, Texas
2025-04-25
Active, closed
Eli Lilly and Company
Phase 3
905
California, Colorado, Georgia, Hawaii, Idaho, Illinois, Indiana, Iowa
2025-04-25
Recruiting
Mirati Therapeutics Inc.
Phase 3
630
Alabama, Arkansas, California, Colorado, Delaware, Florida, Georgia, Illinois
2025-04-24
By invitation
QED Therapeutics, a BridgeBio company
Phase 2/3
24
California, Colorado, District of Columbia, Maryland, Missouri, Ohio, Tennessee, Wisconsin
2025-04-22
Recruiting
An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)
NCT06951217Progressive Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis (IPF)
Avalyn Pharma Inc.
Phase 2
340
Alabama, California, Colorado, Connecticut, Florida, Georgia, Kansas, Maryland
2025-04-17
Recruiting
A Trial to Investigate Benralizumab in Children With Eosinophilic Diseases
NCT06512883Eosinophilic Granulomatosis With Polyangiitis (EGPA), Hypereosinophilia Syndrome (HES)
AstraZeneca
Phase 3
14
Colorado, Ohio
2025-04-17
Active, closed
EyeBiotech Ltd.
Phase 2/3
1,054
Arizona, Arkansas, California, Colorado, Connecticut, Florida, Illinois, Iowa
2025-04-16
Recruiting
Pfizer
Phase 3
550
Alabama, Arizona, California, Colorado, Florida, Idaho, Iowa, Kansas
2025-04-16
Active, closed
Merck Sharp & Dohme LLC
Phase 2
440
Arizona, California, Colorado, Connecticut, Florida, Georgia, Kentucky, Nebraska
2025-04-16
Active, closed
Regeneron Pharmaceuticals
Phase 2
28
California, Colorado, Kansas, Michigan, New Jersey, Tennessee, Texas, Virginia
2025-04-14
Active, closed
Definium Therapeutics US, Inc.
Phase 3
149
Arkansas, California, Colorado, Florida, Illinois, Maryland, Massachusetts, Missouri
2025-04-14
Recruiting
Merck Sharp & Dohme LLC
Phase 2
594
Alabama, Arizona, Arkansas, California, Colorado, Delaware, District of Columbia, Florida
2025-04-11
Recruiting
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
NCT06906341Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Neoplasms, Endometrial Cancer
Corcept Therapeutics
Phase 2
270
Alabama, California, Colorado, Florida, Illinois, Minnesota, Missouri, New Mexico
2025-04-11
Recruiting
CERo Therapeutics Holdings, Inc.
Phase 1
18
California, Colorado, Tennessee, Texas, Washington
2025-04-07
Recruiting
Vifor Pharma, Inc.
Phase 2
36
Colorado, Florida, Georgia, Illinois, Massachusetts, Missouri, New York, North Carolina
2025-04-06
Recruiting
FORWARD CAD IDE Study
NCT06662500Coronary Arterial Disease (CAD)
Shockwave Medical, Inc.
Not applicable
408
California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Massachusetts, Minnesota
2025-04-04
Recruiting
Corza Medical GmbH
Phase 3
116
California, Colorado, District of Columbia, Illinois, Indiana, Kentucky, Missouri, North Carolina
2025-04-02
Recruiting
Coherus Oncology, Inc.
Phase 1
154
Arizona, California, Colorado, Georgia, Louisiana, Michigan, Nevada, New Mexico
2025-04-01
Active, closed
Teva Branded Pharmaceutical Products R&D LLC
Phase 2
50
California, Colorado, Florida, Georgia, Louisiana, Michigan, Minnesota, New York
2025-03-31
Recruiting
A Study of PHST001 in Advanced Solid Tumors
NCT06840886Advanced Solid Tumors, Ovarian Cancer, Endometrial Cancer, Cholangiocarcinoma
Pheast Therapeutics
Phase 1
426
California, Colorado, Connecticut, Illinois, Massachusetts, Michigan, New York, North Carolina
2025-03-31
Recruiting
A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
NCT06655246Gastrointestinal Stromal Tumor (GIST), Gastrointestinal Stromal Cancer, Gastrointestinal Stromal Neoplasm, Gastrointestinal Stromal Tumor, Malignant
Kura Oncology, Inc.
Phase 1
135
Alabama, Arizona, California, Colorado, Connecticut, Florida, Illinois, Iowa
2025-03-27
Active, closed
Incyte Corporation
Phase 1
30
California, Colorado, District of Columbia, Florida, Maryland, New Jersey, Pennsylvania, Tennessee
2025-03-27
Recruiting
Takeda
Phase 4
200
Alabama, Arizona, Arkansas, California, Colorado, Florida, Georgia, Illinois
2025-03-27
Active, closed
Evaluation of D-Fi for the Treatment of Wounds Due to DEB
NCT06892639Dystrophic Epidermolysis Bullosa
Castle Creek Biosciences, LLC.
Phase 3
32
California, Colorado, Massachusetts
2025-03-27
Recruiting
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
NCT07029399HR+ Breast Cancer, Triple Negative Breast Cancer (TNBC), CCNE1 Amplified Advanced Solid Tumors, HR+ HER2- Breast Cancer
NiKang Therapeutics, Inc.
Phase 1
361
California, Colorado, Connecticut, District of Columbia, Florida, Iowa, Massachusetts, Michigan
2025-03-25
Recruiting
Accent Therapeutics
Phase 1/2
218
Colorado, Florida, Michigan, Missouri, Nebraska, New York, Tennessee, Texas
2025-03-21
Recruiting
Bayer
Phase 1/2
450
Alabama, California, Colorado, Florida, Massachusetts, Michigan, New York, Tennessee
2025-03-21
Active, closed
Sun Pharmaceutical Industries Limited
Phase 3
206
California, Colorado, Florida, Georgia, Indiana, Michigan, Nebraska, New York
2025-03-21
Active, closed
Astria Therapeutics, Inc.
Phase 3
157
Alabama, Arizona, Arkansas, California, Colorado, Florida, Maryland, Massachusetts
2025-03-20
Active, closed
TrueBinding, Inc.
Phase 2
62
California, Colorado, Florida, Illinois, Indiana, Kansas, Michigan, New York
2025-03-20
Active, closed
Merck Sharp & Dohme LLC
Phase 2
60
Alabama, California, Colorado, Maryland, Oregon, Texas, Virginia
2025-03-20
Recruiting
Biohaven Therapeutics Ltd.
Phase 1
140
California, Colorado, Florida, Michigan, North Carolina, Ohio, South Carolina, Tennessee
2025-03-20
Recruiting
Immunovant Sciences GmbH
Phase 2
162
Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Illinois, Kansas
2025-03-18
Recruiting
Hoffmann-La Roche
Phase 3
600
Alabama, Arizona, California, Colorado, Florida, Georgia, Idaho, Illinois
2025-03-17
Recruiting
AstraZeneca
Phase 3
11,300
Alabama, Alaska, Arizona, California, Colorado, Connecticut, Florida, Georgia
2025-03-14
Active, closed
Novartis Pharmaceuticals
Phase 3
196
Alabama, Arizona, California, Colorado, District of Columbia, Florida, Georgia, Indiana
2025-03-13
Active, closed
Novartis Pharmaceuticals
Phase 2
126
Colorado, Florida, Illinois, Massachusetts, Michigan, Minnesota, North Carolina, Oregon
2025-03-13
Active, closed
Celgene
Phase 3
960
Alabama, Arizona, California, Colorado, District of Columbia, Florida, Georgia, Illinois
2025-03-13
Recruiting
A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)
NCT06833073Urinary Bladder Neoplasms, Non-Muscle Invasive Bladder Neoplasms, Carcinoma in Situ
Merck Sharp & Dohme LLC
Phase 2
308
California, Colorado, Florida, Illinois, Louisiana, Missouri, Nebraska, New York
2025-03-11
Recruiting
Iovance Biotherapeutics, Inc.
Phase 1/2
42
Colorado, North Carolina, Tennessee
2025-03-11
Recruiting
Halozyme Therapeutics
Phase 3
100
California, Colorado, Florida, Illinois, Massachusetts, Minnesota, Missouri, Nevada
2025-03-07
Recruiting
Hoffmann-La Roche
Phase 2
130
Alaska, California, Colorado, Florida, Idaho, Illinois, Iowa, Kentucky
2025-03-05
Active, closed
Eli Lilly and Company
Phase 3
643
California, Colorado, Connecticut, Florida, Georgia, Hawaii, Illinois, Kentucky
2025-03-05
Recruiting
GlaxoSmithKline
Phase 1/2
305
California, Colorado, New York, North Carolina, Ohio
2025-03-04
Recruiting
Tyra Biosciences, Inc
Phase 2
92
California, Colorado, Delaware, Maryland, Missouri, North Carolina, Tennessee, Texas
2025-03-04
Recruiting
AstraZeneca
Phase 3
5,000
Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2025-03-03
Active, closed
Takeda
Phase 3
1,583
Arizona, California, Colorado, Florida, Georgia, Illinois, Louisiana, Maryland
2025-03-03
Recruiting
Vanda Pharmaceuticals
Phase 3
500
Arizona, Arkansas, California, Colorado, Florida, Georgia, Illinois, Indiana
2025-03-03
Active, closed
4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration
NCT06864988Macular Neovascularization Secondary to Age-Related Macular Degeneration
4D Molecular Therapeutics
Phase 3
480
Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia, Hawaii
2025-03-03
Recruiting
AstraZeneca
Phase 3
840
Alaska, Arizona, California, Colorado, Delaware, Florida, Georgia, Illinois
2025-03-01
Active, closed
Aerin Medical
Observational
400
Alabama, Arizona, California, Colorado, Florida, Illinois, Kentucky, Michigan
2025-02-28
Active, closed
Adverum Biotechnologies, Inc.
Phase 3
311
Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia, Illinois
2025-02-28
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
327
Colorado, Florida, Illinois, Massachusetts, New Jersey, New York, Oregon, Tennessee
2025-02-27
Recruiting
Novartis Pharmaceuticals
Phase 2/3
443
Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois, Indiana
2025-02-27
Recruiting
Takeda
Phase 3
171
Arkansas, California, Colorado, District of Columbia, Georgia, Indiana, Iowa, Kentucky
2025-02-27
Recruiting
Summit Therapeutics
Phase 3
780
Arizona, Arkansas, California, Colorado, Florida, Georgia, Illinois, Indiana
2025-02-27
Recruiting
A Phase 1 Study of IM-1021 in Participants With Advanced Cancer
NCT06823167Solid Malignancies, Hematologic Malignancies
Immunome, Inc.
Phase 1
190
California, Colorado, Connecticut, Florida, Georgia, Iowa, Kentucky, Michigan
2025-02-26
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
181
Colorado, Massachusetts, New Jersey, South Carolina, Virginia
2025-02-26
Recruiting
Amgen
Phase 3
844
Arizona, California, Colorado, Florida, Massachusetts, Michigan, Missouri, New Jersey
2025-02-25
Recruiting
Prevail Global Study
NCT06535854Coronary Artery Disease
Medtronic Vascular
Not applicable
1,205
Alabama, Arizona, Arkansas, California, Colorado, District of Columbia, Florida, Georgia
2025-02-24
Active, closed
Efficacy and Safety Study of Halneuron in the Treatment of Chemotherapy-Induced Neuropathic Pain
NCT06848348Chemotherapy Induced Neuropathic Pain, Chemotherapy Induced Pain Neuropathy, Chemotherapy Induced Pain
Dogwood Therapeutics Inc.
Phase 2
240
Alabama, Arizona, California, Colorado, Florida, Illinois, Louisiana, Missouri
2025-02-21
By invitation
Axsome Therapeutics, Inc.
Phase 3
236
California, Colorado, Connecticut, Florida, Georgia, Kansas, Massachusetts, Missouri
2025-02-20
Active, closed
A Study to Assess the Safety, Tolerability, and Efficacy of IMVT-1402 in Participants With Cutaneous Lupus Erythematosus (CLE)
NCT06980805Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus
Immunovant Sciences GmbH
Phase 2
56
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Massachusetts
2025-02-19
Recruiting
Study of LHP588 in Subjects With P. Gingivalis-Positive Alzheimer's Disease
NCT06847321Alzheimer Disease, Alzheimer Disease Due to P. Gingivalis
Lighthouse Pharmaceuticals, Inc.
Phase 2
300
Arizona, California, Colorado, Florida, Georgia, Kansas, Louisiana, Maryland
2025-02-17
Recruiting
Bristol-Myers Squibb
Phase 1/2
286
California, Colorado, New Jersey, New York, North Carolina, Washington
2025-02-17
Recruiting
VIVEX Biologics, Inc.
Not applicable
325
California, Colorado, Florida, Georgia, Indiana, Kansas, Kentucky, Louisiana
2025-02-17
Recruiting
Novo Nordisk A/S
Phase 3
510
Alabama, Arizona, Arkansas, California, Colorado, Delaware, District of Columbia, Florida
2025-02-17
Recruiting
March Biosciences Inc
Phase 2
46
California, Colorado, Florida, Iowa, Massachusetts, Nebraska, New York, North Carolina
2025-02-15
By invitation
Longboard Pharmaceuticals
Phase 3
324
Arkansas, California, Colorado, Florida, Idaho, Iowa, Maryland, Massachusetts
2025-02-12
Recruiting
Splice Bio
Phase 1/2
57
Colorado, Florida, Massachusetts, Oregon, Texas
2025-02-11
Recruiting
AbbVie
Phase 3
130
Arizona, California, Colorado, Florida, Georgia, Illinois, Kansas, Louisiana
2025-02-11
Recruiting
Healx Limited
Phase 2
25
Alabama, California, Colorado, District of Columbia, Illinois, Indiana, Maryland, Missouri
2025-02-10
Recruiting
Janssen Research & Development, LLC
Phase 3
50
Alabama, California, Colorado, Florida, Illinois, Indiana, Iowa, Michigan
2025-02-10
Active, closed
Rivermark Medical
Not applicable
215
California, Colorado, Florida, Illinois, Louisiana, Michigan, Nevada, New York
2025-02-10
Active, closed
GlaxoSmithKline
Phase 2
307
Arkansas, California, Colorado, Connecticut, Florida, Illinois, Louisiana, Michigan
2025-02-10
Recruiting
100-Year Human Aging Study
NCT07563777Aging, Aging Well, All-Cause Mortality, Mortality
Longevity Metrics, Inc.
Observational
1,000,000
Colorado
2025-02-09
Recruiting
A Phase 1b/2a Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With mCRPC
NCT06785636mCRPC (Metastatic Castration-resistant Prostate Cancer), Prostate Cancer
Pathos AI, Inc.
Phase 1/2
120
California, Colorado, Florida, Georgia, Illinois, Indiana, Louisiana, Maryland
2025-02-07
Recruiting
Takeda
Phase 2
96
California, Colorado, Florida, Missouri, North Carolina, Ohio, South Carolina, Texas
2025-02-07
Active, closed
Genmab
Phase 3
584
Alaska, Arizona, California, Colorado, Connecticut, Florida, Georgia, Hawaii
2025-02-07
Recruiting
Janssen Research & Development, LLC
Phase 1/2
190
Colorado, Connecticut, Florida, Louisiana, Massachusetts, Michigan, Nebraska, New York
2025-02-06
Recruiting
Medtronic Cardiovascular
Observational
225
Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Indiana
2025-02-06
Active, closed
Annovis Bio Inc.
Phase 3
861
Arizona, California, Colorado, Connecticut, Florida, Georgia, Hawaii, Illinois
2025-02-04
Recruiting
A Study to Investigate the Safety and Efficacy of KQB365 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies
NCT06720987KRAS G12C Mutation, KRAS G12S Mutation, Solid Tumor Malignancies, CRC (Colorectal Cancer)
Kumquat Biosciences Inc.
Phase 1
140
Arizona, Colorado, Florida, Massachusetts, Michigan, Minnesota, Ohio, Oklahoma
2025-02-04
Active, closed
WATER IV Prostate Cancer
NCT06651632Localized Prostate Cancer
PROCEPT BioRobotics
Not applicable
280
Arizona, California, Colorado, Florida, Georgia, Idaho, Illinois, Maryland
2025-02-03
Recruiting
Syndeio Biosciences, Inc
Phase 2
164
Alabama, California, Colorado, Connecticut, Florida, Georgia, Illinois, Kansas
2025-02-03
Recruiting
Study of Olutasidenib and Temozolomide in HGG
NCT06161974High Grade Glioma, Astrocytoma, Astrocytoma, Grade III, Astrocytoma, Grade IV
Rigel Pharmaceuticals
Phase 2
60
Colorado, District of Columbia, Florida, Illinois, Massachusetts, North Carolina, Ohio, Pennsylvania
2025-02-01
By invitation
Pharvaris Netherlands B.V.
Phase 3
170
Alabama, Arizona, Arkansas, California, Colorado, Illinois, Missouri, Nevada
2025-02-01
Active, closed
Boehringer Ingelheim
Phase 2
150
Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois, Kentucky
2025-01-31
Recruiting
Allotera Therapeutics
Phase 2
125
California, Colorado, District of Columbia, Florida, Georgia, Missouri, New York, Ohio
2025-01-31
Recruiting
FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
NCT06788990Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
Bicara Therapeutics
Phase 2/3
650
Alabama, Arizona, California, Colorado, Delaware, Florida, Illinois, Indiana
2025-01-28
Recruiting
A Long-Term Study of ALKS 2680 in Subjects With Narcolepsy and Idiopathic Hypersomnia
NCT06767683Narcolepsy Type 1, Narcolepsy Type 2, Idiopathic Hypersomnia
Alkermes, Inc.
Phase 2/3
786
Alabama, Arizona, Arkansas, California, Colorado, Florida, Georgia, Illinois
2025-01-27
By invitation
Verismo Therapeutics
Observational
60
Colorado, Georgia, Kansas, New Jersey, Pennsylvania, Texas, Wisconsin
2025-01-27
Recruiting
Incyte Corporation
Phase 3
180
Alabama, Arizona, Arkansas, California, Colorado, Florida, Georgia, Idaho
2025-01-24
Recruiting
DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
NCT06388421Pulmonary Hypertension Due to Lung Diseases and Hypoxia, Pulmonary Hypertension, Interstitial Lung Disease
United Therapeutics
Observational
900
Alabama, Arizona, California, Colorado, District of Columbia, Florida, Georgia, Illinois
2025-01-23
Active, closed
Astellas Pharma Global Development, Inc.
Observational
488
Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois, Iowa
2025-01-22
Recruiting
Ascentage Pharma Group Inc.
Phase 3
490
Alabama, Arizona, California, Colorado, Florida, Illinois, Indiana, Iowa
2025-01-22
Recruiting
Incyte Corporation
Phase 3
240
Alabama, Arizona, California, Colorado, District of Columbia, Florida, Georgia, Illinois
2025-01-21
Recruiting
A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease
NCT06680830Parkinson Disease, Parkinson, Idiopathic Parkinson Disease, Early Parkinson Disease (Early PD)
Neuron23 Inc.
Phase 2
150
Arizona, Arkansas, California, Colorado, Florida, Georgia, Illinois, Kansas
2025-01-17
Active, closed
argenx
Phase 3
631
Arizona, California, Colorado, Florida, Georgia, Idaho, Illinois, Indiana
2025-01-15
Active, closed
Intellia Therapeutics
Phase 3
80
Arizona, California, Colorado, Florida, Massachusetts, Missouri, New York, Ohio
2025-01-15
Recruiting
Immatics US, Inc.
Phase 3
450
Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois, Maryland
2025-01-14
Recruiting
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
NCT06695845Breast Cancer, Gastric Cancer, Esophageal Cancer, Gastroesophageal Cancer
Jazz Pharmaceuticals
Phase 2
200
Arizona, Colorado, Florida, Illinois, Kansas, Michigan, New York, Pennsylvania
2025-01-14
Active, closed
Quanta Therapeutics
Phase 1
237
Colorado, Connecticut, Florida, Michigan, North Carolina, Tennessee, Texas, Utah
2025-01-14
Recruiting
HYDRAFIL-D: HYDRogel Augmentation For Intervertebral Lumbar Discs
NCT06011551Degenerative Disc Disease (DDD)
ReGelTec, Inc.
Not applicable
225
Alabama, California, Colorado, District of Columbia, Florida, Georgia, Kansas, Louisiana
2025-01-13
Active, closed
Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)
NCT06700343Relapsing-remitting Multiple Sclerosis (RRMS)
Amgen
Phase 3
152
Alabama, Arizona, California, Colorado, Connecticut, Florida, Hawaii, Illinois
2025-01-13
Active, closed
Immunovant Sciences GmbH
Phase 2
120
Arizona, California, Colorado, Florida, Georgia, Illinois, Maryland, Massachusetts
2025-01-10
Recruiting
Eli Lilly and Company
Phase 3
55
Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2025-01-10
Recruiting
Pan-tumor MRD Study
NCT06605404Muscle Invasive Bladder Urothelial Carcinoma, Esophageal Cancer, Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma, Melanoma (Skin Cancer)
Paradigm Health
Observational
1,350
Alabama, Arizona, Arkansas, California, Colorado, Florida, Georgia, Illinois
2025-01-08
Recruiting
BioNTech SE
Phase 2/3
1,580
Alabama, Alaska, California, Colorado, District of Columbia, Florida, Georgia, Indiana
2025-01-07
Active, closed
Pfizer
Phase 3
1,037
Alabama, Arizona, Arkansas, California, Colorado, District of Columbia, Florida, Georgia
2025-01-06
Recruiting
Loxo Oncology, Inc.
Phase 2
249
Arizona, California, Colorado, Florida, Georgia, Iowa, Kentucky, Maryland
2025-01-03
Active, closed
Cochlear
Not applicable
56
California, Colorado, Iowa, Michigan, Missouri, New York, Ohio, Oregon
2025-01-03
Recruiting
Takeda
Phase 3
396
California, Colorado, Florida, Indiana, Kentucky, New York, South Carolina, South Dakota
2025-01-02
Active, closed
AstraZeneca
Phase 1/2
242
Alabama, California, Colorado, Florida, Georgia, Illinois, Iowa, Kentucky
2024-12-30
Recruiting
Study of ISM6331 in Participants With Advanced/Metastatic Mesothelioma or Other Advanced Solid Tumors
NCT06566079Malignant Mesothelioma, Metastatic Malignant Solid Tumor, Advanced Solid Tumor
InSilico Medicine Hong Kong Limited
Phase 1/2
160
Colorado, Illinois, Ohio, Pennsylvania, Tennessee, Texas
2024-12-27
Active, closed
Amgen
Phase 2
61
California, Colorado, Connecticut, District of Columbia, Louisiana, Michigan, Tennessee, Texas
2024-12-26
Recruiting
Long-term Follow-up (LTFU) Study of Participants in Any iECURE Protocol Using an Investigational Product (IP)
NCT06805695Ornithine Transcarbamylase Deficiency, Ornithine Transcarbamylase Deficiency Disease, Urea Cycle Disorders, Inborn
iECURE, Inc.
Observational
13
Colorado, New York
2024-12-23
Active, closed
Palvella Therapeutics, Inc.
Phase 2
15
California, Colorado, Maryland, Minnesota, North Carolina, Ohio, Pennsylvania, Utah
2024-12-20
Active, closed
AbbVie
Phase 2
83
Arizona, California, Colorado, Florida, Illinois, Nebraska, New York, Oregon
2024-12-19
Recruiting
Cytokinetics
Phase 3
1,800
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia
2024-12-19
Active, closed
Cleerly, Inc.
Not applicable
1,000
Alabama, California, Colorado, Florida, Illinois, Iowa, Kentucky, Louisiana
2024-12-18
Recruiting
A Study to Assess the Incidence of Skin Cancers in Patients With Epidermolysis Bullosa Receiving Filsuvez
NCT06423573Epidermolysis Bullosa, Dystrophic, Epidermolysis Bullosa, Junctional
Chiesi Farmaceutici S.p.A.
Observational
170
California, Colorado, Florida, Ohio, Pennsylvania, South Carolina
2024-12-18
Active, closed
argenx
Phase 3
154
Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Illinois, Indiana
2024-12-18
Active, closed
Vertex Pharmaceuticals Incorporated
Phase 3
455
Alabama, Arizona, California, Colorado, District of Columbia, Florida, Georgia, Idaho
2024-12-18
Active, closed
Asahi Kasei Therapeutics, AB
Phase 4
60
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Kentucky
2024-12-17
Recruiting
Replimune, Inc.
Phase 2/3
280
Arizona, California, Colorado, District of Columbia, Florida, Georgia, Illinois, Iowa
2024-12-17
Recruiting
Cabaletta Bio
Phase 1/2
24
California, Colorado, Florida, Illinois, Kansas, Massachusetts, Minnesota, New York
2024-12-17
Recruiting
Using CTA Measures to Define Cardiac Risk In NFL Alumni
NCT06831409Coronary Artery Disease (CAD), Heart Disease, Coronary Atherosclerosis
HeartFlow, Inc.
Observational
300
Colorado
2024-12-17
Recruiting
Immunovant Sciences GmbH
Phase 2
240
Arizona, California, Colorado, Delaware, District of Columbia, Florida, Georgia, Indiana
2024-12-17
Recruiting
Janssen Research & Development, LLC
Phase 2
480
Alabama, Arizona, California, Colorado, Connecticut, Delaware, District of Columbia, Florida
2024-12-16
Recruiting
Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors
NCT06784193Advanced or Metastatic ER+ HER2- Breast Cancer (mBC), Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC), Advanced or Metastatic Castration-Resistant Prostate Cancer (mCRPC), Metastatic Breast Cancer
Olema Oncology, Inc.
Phase 1
180
Arizona, Colorado, Florida, Louisiana, Massachusetts, Michigan, New York, Ohio
2024-12-16
Active, closed
GlaxoSmithKline
Phase 1/2
14
California, Colorado, Michigan, New York, Pennsylvania
2024-12-13
Active, closed
Arcus Biosciences, Inc.
Phase 3
610
Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois, Indiana
2024-12-13
Recruiting
Study of GalaFLEX LITE™ Scaffold in Treatment of Capsular Contracture After Breast Implant Augmentation
NCT05945329Capsular Contracture Associated With Breast Implant, Capsular Contracture Grade III, Capsular Contracture Grade IV
C. R. Bard
Not applicable
250
Arizona, California, Colorado, Florida, Georgia, Illinois, Indiana, Louisiana
2024-12-12
Recruiting
Janssen Research & Development, LLC
Phase 3
700
Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia, Illinois
2024-12-12
Recruiting
Biogen
Observational
300
California, Colorado, Florida, Pennsylvania
2024-12-12
Active, closed
Definium Therapeutics US, Inc.
Phase 3
214
Arizona, California, Colorado, Florida, Georgia, Illinois, Massachusetts, New Jersey
2024-12-11
Recruiting
Boehringer Ingelheim
Phase 2
80
Arizona, Colorado, Florida, Illinois, Kansas, New York, North Carolina, Texas
2024-12-11
Active, closed
Hoffmann-La Roche
Phase 3
350
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Indiana
2024-12-11
Recruiting
Deciphera Pharmaceuticals, LLC
Phase 1/2
155
Arizona, California, Colorado, Florida, Massachusetts, Michigan, Minnesota, New York
2024-12-10
Active, closed
Kumquat Biosciences Inc.
Phase 1
13
California, Colorado, Florida, Michigan, North Carolina, Ohio, Tennessee, Texas
2024-12-09
Active, closed
Vicore Pharma AB
Phase 2
378
Alabama, California, Colorado, Florida, Georgia, Illinois, Kansas, Michigan
2024-12-09
Recruiting
Pfizer
Phase 3
2,330
Alabama, Arkansas, California, Colorado, District of Columbia, Florida, Georgia, Idaho
2024-12-08
Active, closed
Otsuka Pharmaceutical Development & Commercialization, Inc.
Phase 2
56
Alabama, California, Colorado, Massachusetts, South Dakota, Texas
2024-12-05
Active, closed
Janssen Research & Development, LLC
Phase 3
655
California, Colorado, Florida, Georgia, Illinois, Iowa, Kansas, Michigan
2024-12-04
Active, closed
Left Ventricular Impella Device Real-World Evaluation in Pediatric Patients
NCT07943182Cardiogenic Shock, Heart Failure, Acute Decompensated Heart Failure (ADHF), Cardiomyopathy
Abiomed Inc.
Observational
60
Arizona, California, Colorado, Florida, Georgia, Illinois, Kentucky, Massachusetts
2024-12-03
Active, closed
Biogen
Phase 3
132
California, Colorado, Illinois, Kansas, Louisiana, Minnesota, Missouri, Nebraska
2024-12-03
Recruiting
OSE Immunotherapeutics
Phase 3
363
California, Colorado, Connecticut, District of Columbia, Florida, Illinois, Kansas, Louisiana
2024-12-03
Active, closed
H. Lundbeck A/S
Phase 3
401
Arizona, Arkansas, California, Colorado, Connecticut, Florida, Indiana, Maryland
2024-12-03
Recruiting
Novo Nordisk A/S
Phase 2
465
California, Colorado, Florida, Illinois, Indiana, Michigan, Missouri, New York
2024-12-02
Active, closed
ViiV Healthcare
Phase 3
326
Alabama, California, Colorado, Connecticut, Delaware, District of Columbia, Florida, Georgia
2024-12-02
Recruiting
Merck Sharp & Dohme LLC
Phase 3
3,082
Alabama, Arizona, California, Colorado, Florida, Georgia, Idaho, Illinois
2024-12-02
Active, closed
Retrospective PNS Study
NCT06832449Chronic Pain
Curonix LLC
Observational
200
Colorado
2024-12-01
Active, closed
Ocular Therapeutix, Inc.
Phase 3
825
Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois, Indiana
2024-11-27
Recruiting
AstraZeneca
Phase 3
1,160
Alabama, Arizona, California, Colorado, Connecticut, Delaware, Florida, Georgia
2024-11-27
Active, closed
EyePoint Pharmaceuticals, Inc.
Phase 3
400
Arizona, California, Colorado, Connecticut, Florida, Illinois, Indiana, Kentucky
2024-11-27
Active, closed
Vaxcyte, Inc.
Phase 2
900
Arkansas, California, Colorado, Florida, Idaho, Kentucky, Louisiana, Nebraska
2024-11-25
Active, closed
Novartis Pharmaceuticals
Phase 4
24
California, Colorado, Illinois, Massachusetts
2024-11-25
Recruiting
Shanghai Henlius Biotech
Phase 3
550
California, Colorado, Florida, Illinois, Iowa, Missouri, Nebraska, Nevada
2024-11-22
Active, closed
Luna Diabetes
Not applicable
120
California, Colorado, Minnesota
2024-11-22
Active, closed
Regeneron Pharmaceuticals
Observational
368
Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia, Illinois
2024-11-22
Recruiting
Intra-Cellular Therapies, Inc.
Phase 3
160
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Massachusetts
2024-11-22
Recruiting
RTI Surgical
Not applicable
467
Arkansas, California, Colorado, Kansas, Missouri, New York, Ohio, Oklahoma
2024-11-22
Recruiting
UCB Biopharma SRL
Phase 3
450
Arizona, Arkansas, California, Colorado, Florida, Georgia, Illinois, Indiana
2024-11-21
Active, closed
CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.
NCT06690775Epithelial Ovarian Cancer, Primary Peritoneal, Fallopian Tube Cancer, Endometrioid Ovarian Cancer
TORL Biotherapeutics, LLC
Phase 2
230
Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois, Maryland
2024-11-20
Recruiting
A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
NCT06369285Hormone Receptor Positive HER-2 Negative Breast Cancer, Metastatic Breast Cancer, Recurrent Breast Cancer
Puma Biotechnology, Inc.
Phase 2
225
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois
2024-11-19
Active, closed
Daiichi Sankyo
Phase 3
700
Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Illinois
2024-11-19
Recruiting
Ensoma
Observational
60
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, District of Columbia
2024-11-18
Recruiting
Eli Lilly and Company
Phase 3
125
Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois, Indiana
2024-11-18
Active, closed
Pfizer
Phase 3
636
Arizona, California, Colorado, Illinois, Massachusetts, Michigan, Missouri, New Jersey
2024-11-15
Recruiting
Aventix Medical Inc.
Not applicable
30
Colorado, Mississippi, Texas
2024-11-15
Recruiting
Genentech, Inc.
Phase 1
410
California, Colorado, Connecticut, Florida, Illinois, Massachusetts, Michigan, New York
2024-11-14
Recruiting
Neurona Therapeutics
Phase 1/2
10
Arkansas, California, Colorado, Illinois, Iowa, New York, North Carolina, Oregon
2024-11-14
Recruiting
Boehringer Ingelheim
Phase 3
1,590
Arizona, California, Colorado, Connecticut, Florida, Georgia, Indiana, Iowa
2024-11-12
Active, closed
Sanofi Pasteur, a Sanofi Company
Phase 1/2
1,530
Arizona, California, Colorado, District of Columbia, Florida, Idaho, Kansas, Maryland
2024-11-11
Active, closed
Longboard Pharmaceuticals
Phase 3
367
Arkansas, California, Colorado, District of Columbia, Florida, Georgia, Idaho, Illinois
2024-11-11
Active, closed
AbbVie
Phase 2
74
California, Colorado, Connecticut, Florida, Georgia, Idaho, Illinois, Indiana
2024-11-08
Active, closed
Efficacy and Safety of VDPHL01 in Males With AGA
NCT06724614Androgenetic Alopecia, AGA, Male Pattern Baldness
Veradermics, Inc.
Phase 2/3
480
Alabama, Arizona, Arkansas, California, Colorado, Florida, Georgia, Idaho
2024-11-06
Recruiting
AbbVie
Phase 3
264
California, Colorado, Florida, Illinois, Maryland, Missouri, Nevada, New Jersey
2024-11-05
Active, closed
Takeda
Phase 3
53
California, Colorado, Florida, Georgia, Illinois, Louisiana, New York, North Carolina
2024-11-04
Recruiting
Glycogen Storage Disease Type Ia (GSDIa) Disease Monitoring Program
NCT06636383Glycogen Storage Disease Type Ia
Ultragenyx Pharmaceutical Inc
Observational
140
California, Colorado, Connecticut, Michigan, North Carolina, Ohio, Pennsylvania, Texas
2024-11-04
Active, closed
Merck Sharp & Dohme LLC
Phase 1/2
180
California, Colorado, District of Columbia, Florida, Georgia, Illinois, Nevada, New York
2024-11-03
Recruiting
SynKIR-310 for Relapsed/Refractory B-NHL
NCT06544265B Cell Lymphoma, NHL, Adult, Mantle Cell Lymphoma, Relapsed Non-Hodgkin Lymphoma
Verismo Therapeutics
Phase 1
36
Colorado, Georgia, Kansas, New Jersey, Pennsylvania
2024-11-01
Active, closed
Eli Lilly and Company
Phase 3
800
Arizona, California, Colorado, Connecticut, Florida, Georgia, Hawaii, Illinois
2024-11-01
Recruiting
Abivax S.A.
Phase 2
212
Alabama, Arizona, California, Colorado, Florida, Illinois, Iowa, Massachusetts
2024-10-30
Recruiting
Regeneron Pharmaceuticals
Phase 3
975
Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia, Illinois
2024-10-30
Recruiting
The THOR IDE Study
NCT05916950Peripheral Artery Disease, Peripheral Artery Stenosis, Peripheral Artery Calcification, PAD
Philips Clinical & Medical Affairs Global
Not applicable
155
California, Colorado, Florida, Iowa, Louisiana, Maine, Massachusetts, Michigan
2024-10-29
Recruiting
Shanghai Allink Biotherapeutics Co., Ltd.
Phase 1/2
202
Colorado, Florida, Louisiana, Tennessee
2024-10-24
Recruiting
Novartis Pharmaceuticals
Phase 1/2
232
Arizona, California, Colorado, Florida, Georgia, Kansas, Kentucky, Massachusetts
2024-10-24
Active, closed
Eli Lilly and Company
Phase 3
1,400
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Idaho
2024-10-24
Recruiting
Shoulder Innovations Clinical Data Registry
NCT06754150Shoulder Arthroplasty
Shoulder Innovations
Observational
2,500
Alabama, California, Colorado, Florida, Georgia, Maryland, Massachusetts, Michigan
2024-10-23
Active, closed
EyePoint Pharmaceuticals, Inc.
Phase 3
400
Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia, Hawaii
2024-10-22
Recruiting
Ionis Pharmaceuticals, Inc.
Phase 1/2
48
California, Colorado, Maryland, Massachusetts, Minnesota, Pennsylvania, Tennessee, Texas
2024-10-21
Active, closed
Esprit BTK Post-Approval Study
NCT06656364Chronic Limb-Threatening Ischemia
Abbott Medical Devices
Not applicable
200
Arizona, California, Colorado, District of Columbia, Florida, Georgia, Illinois, Indiana
2024-10-21
Active, closed
Pfizer
Phase 3
609
Alabama, Arizona, California, Colorado, Florida, Illinois, Kentucky, Maine
2024-10-21
Recruiting
Merck Sharp & Dohme LLC
Phase 3
680
Arizona, California, Colorado, Connecticut, Florida, Idaho, Illinois, Indiana
2024-10-21
Recruiting
Janssen Research & Development, LLC
Phase 3
1,000
Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2024-10-18
Recruiting
argenx
Phase 3
69
Arizona, California, Colorado, Connecticut, District of Columbia, Illinois, Iowa, Louisiana
2024-10-18
Recruiting
Vertex Pharmaceuticals Incorporated
Phase 2
300
Alabama, California, Colorado, Florida, Georgia, Idaho, Illinois, Michigan
2024-10-18
Active, closed
J-Valve Transfemoral Pivotal Study
NCT06455787Aortic Valve Regurgitation, Aortic Valve Disease Mixed
JC Medical, Inc., an affiliate of Edwards Lifesciences LLC
Not applicable
194
Arizona, California, Colorado, District of Columbia, Florida, Georgia, Illinois, Kansas
2024-10-17
Active, closed
Uniquity One (UNI)
Phase 2
184
Alabama, Arizona, California, Colorado, Connecticut, Florida, Idaho, Illinois
2024-10-16
Active, closed
Revolution Medicines, Inc.
Phase 3
500
Arizona, California, Colorado, Florida, Hawaii, Illinois, Maryland, Massachusetts
2024-10-16
Recruiting
A Study of JNJ-89402638 for Metastatic Colorectal and Gastric Cancers
NCT06663319Colorectal Neoplasms, Gastrointestinal Neoplasms
Janssen Research & Development, LLC
Phase 1
260
Arizona, Colorado, Florida, Indiana, Michigan, Washington
2024-10-15
Active, closed
Ipsen
Observational
424
California, Colorado, Connecticut, Florida, Massachusetts, New Jersey, New York, North Carolina
2024-10-14
Recruiting
Boehringer Ingelheim
Phase 3
1,800
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Indiana
2024-10-14
Active, closed
Incyte Corporation
Phase 2
130
Arizona, California, Colorado, Connecticut, Florida, Illinois, Maryland, Missouri
2024-10-11
Active, closed
Eli Lilly and Company
Phase 2
143
Arizona, Arkansas, California, Colorado, Connecticut, Florida, Illinois, Louisiana
2024-10-10
Active, closed
Ipsen
Phase 2
670
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Louisiana
2024-10-10
Active, closed
Gilead Sciences
Phase 3
609
Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2024-10-09
Active, closed
Vaxart
Phase 2
5,485
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida
2024-10-08
Recruiting
Study of ACR-2316 in Specific Advanced Solid Tumors
NCT06667141Specific Advanced Solid Tumors
Acrivon Therapeutics
Phase 1/2
100
Arizona, California, Colorado, Florida, Massachusetts, Michigan, New York, North Carolina
2024-10-08
Active, closed
Gilead Sciences
Phase 3
600
Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2024-10-08
Recruiting
Bristol-Myers Squibb
Phase 3
1,000
Alabama, Arizona, California, Colorado, Florida, Idaho, Illinois, Kansas
2024-10-07
Recruiting
A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
NCT06528314NASH - Nonalcoholic Steatohepatitis, MASH - Metabolic Dysfunction-Associated Steatohepatitis
Akero Therapeutics, Inc
Phase 3
2,150
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida
2024-10-04
Recruiting
BeOne Medicines
Phase 1
310
Arizona, California, Colorado, Connecticut, Illinois, Kansas, Mississippi, New Jersey
2024-10-03
Recruiting
ALTO-100 in Bipolar Disorder With Depression (BD-D)
NCT06656416Bipolar Disorder I or II With a Major Depressive Episode
Alto Neuroscience
Phase 2
200
Alabama, Arizona, Arkansas, California, Colorado, Florida, Georgia, Illinois
2024-10-02
Recruiting
Vertex Pharmaceuticals Incorporated
Phase 3
1,100
Alabama, Arizona, California, Colorado, District of Columbia, Florida, Georgia, Idaho
2024-10-01
Recruiting
Aptevo Therapeutics
Phase 1
39
Colorado, Florida, Kansas, Ohio, Texas
2024-10-01
Recruiting
Abbott Nutrition
Not applicable
96
Arizona, Colorado, Illinois, Michigan, North Carolina, Ohio, Texas
2024-10-01
Recruiting
Ferring Pharmaceuticals
Phase 3
250
Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2024-10-01
Active, closed
SIMPLAAFY Clinical Trial
NCT06521463Atrial Fibrillation, Stroke, Bleeding
Boston Scientific Corporation
Not applicable
1,857
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida
2024-10-01
Recruiting
Ferring Pharmaceuticals
Phase 3
454
Alabama, Arizona, Arkansas, California, Colorado, District of Columbia, Florida, Georgia
2024-10-01
Recruiting
GlaxoSmithKline
Phase 1
845
California, Colorado, Connecticut, Indiana, Massachusetts, Michigan, New Jersey, South Carolina
2024-09-30
By invitation
Sanofi
Phase 2
900
Arizona, Colorado, Florida, Georgia, Massachusetts, Michigan, Missouri, North Carolina
2024-09-30
Active, closed
AstraZeneca
Phase 3
310
California, Colorado, Florida, Massachusetts, Missouri, New Jersey, Oklahoma, Texas
2024-09-30
Active, closed
Stemline Therapeutics, Inc.
Phase 3
4,556
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida
2024-09-27
Recruiting
Registry for Stage 2 Type 1 Diabetes
NCT06481904Type 1 Diabetes
DrugTzield
Sanofi
Observational
200
California, Colorado, Connecticut, Florida, Georgia, Illinois, Indiana, Kentucky
2024-09-27
Active, closed
Boehringer Ingelheim
Phase 3
1,666
Alabama, Arizona, California, Colorado, Connecticut, Delaware, District of Columbia, Florida
2024-09-26
Recruiting
Pfizer
Phase 2
48
California, Colorado, Indiana, Kentucky, Massachusetts, North Carolina, Texas
2024-09-25
Active, closed
Longboard Pharmaceuticals
Phase 3
108
Arkansas, California, Colorado, District of Columbia, Florida, Georgia, Illinois, Maryland
2024-09-25
Active, closed
Nocion Therapeutics
Phase 2
455
Alabama, Arizona, Arkansas, California, Colorado, Florida, Georgia, Illinois
2024-09-24
Active, closed
ModernaTX, Inc.
Phase 3
37,864
Alabama, Arizona, Arkansas, California, Colorado, Florida, Georgia, Idaho
2024-09-24
Active, closed
Cerevance
Phase 3
330
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Kansas
2024-09-20
Active, closed
A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
NCT06561685Metastatic Solid Tumor, Advanced Solid Tumor, Non-small Cell Lung Cancer, SMARCA4-Deficient Tumor
Eli Lilly and Company
Phase 1
340
California, Colorado, Florida, Illinois, Massachusetts, New York, Ohio, Tennessee
2024-09-19
Recruiting
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
NCT06586957Solid Tumor, Advanced Solid Tumor, Solid Tumor, Adult, Metastatic Tumor
NiKang Therapeutics, Inc.
Phase 1
238
Arkansas, California, Colorado, Florida, Georgia, Kansas, Massachusetts, New Jersey
2024-09-19
Active, closed
NS-050/NCNP-03 in Boys With DMD (Meteor50)
NCT06053814Duchenne Muscular Dystrophy
NS Pharma, Inc.
Phase 1/2
20
California, Colorado, Illinois, Kansas, Pennsylvania
2024-09-18
Active, closed
Regeneron Pharmaceuticals
Phase 2
151
California, Colorado, Connecticut, Georgia, Illinois, Massachusetts, Missouri, New Jersey
2024-09-18
Active, closed
Hoffmann-La Roche
Phase 3
400
Alabama, California, Colorado, Florida, Georgia, Idaho, Illinois, Indiana
2024-09-17
Active, closed
Amgen
Phase 1
49
California, Colorado, Connecticut, Minnesota, Missouri, Nevada, New York, Oklahoma
2024-09-17
Active, closed
Pfizer
Observational
300
Arizona, California, Colorado, Florida, Illinois, Maryland, New Jersey, New York
2024-09-17
Recruiting
CG Oncology, Inc.
Phase 2
325
Arizona, Arkansas, California, Colorado, Florida, Georgia, Illinois, Indiana
2024-09-16
Active, closed
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
NCT06586515Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer
Eli Lilly and Company
Phase 1
630
California, Colorado, District of Columbia, Florida, Georgia, Indiana, Massachusetts, Michigan
2024-09-12
Active, closed
A Study of Brepocitinib in Adults With Active, Non-Infectious, Non-Anterior Uveitis
NCT06431373Uveitis, Posterior, Uveitis, Intermediate, Uveitis
Priovant Therapeutics, Inc.
Phase 3
371
Arizona, California, Colorado, Florida, Illinois, Indiana, Kansas, Maryland
2024-09-11
Recruiting
A Phase II Study of Ensifentrine in Non-Cystic Fibrosis Bronchiectasis
NCT06559150Non-cystic Fibrosis Bronchiectasis
Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
Phase 2
284
Alabama, California, Colorado, District of Columbia, Florida, Georgia, Indiana, Iowa
2024-09-11
Recruiting
Regeneron Pharmaceuticals
Phase 1/2
130
Arizona, California, Colorado, Connecticut, Florida, Indiana, Louisiana, Michigan
2024-09-11
Recruiting
Regeneron Pharmaceuticals
Phase 3
560
Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia, Idaho
2024-09-09
Recruiting
Acorn Biolabs Inc.
Observational
500
Alabama, Arizona, California, Colorado, Florida, Illinois, Indiana, Michigan
2024-09-09
Active, closed
Amplitude Vascular Systems (AVS) Lithotripsy POWER PAD 2 Trial
NCT06457685Peripheral Arterial Disease (PAD)
Amplitude Vascular Systems, Inc.
Not applicable
115
Arkansas, California, Colorado, Georgia, Iowa, Missouri, New Jersey, New York
2024-09-05
Recruiting
AbbVie
Phase 2
590
Alabama, California, Colorado, Connecticut, Florida, Georgia, Idaho, Illinois
2024-09-04
Active, closed
Tectonic Therapeutic
Phase 2
191
Arizona, California, Colorado, Florida, Georgia, Idaho, Kentucky, Maryland
2024-09-04
Recruiting
Kardion Inc
Not applicable
310
Arizona, Arkansas, Colorado, Connecticut, Florida, Georgia, Indiana, Massachusetts
2024-09-03
Active, closed
Alpine Immune Sciences Inc, A Subsidiary of Vertex
Phase 3
605
Alabama, Arizona, California, Colorado, Delaware, Florida, Georgia, Idaho
2024-08-30
Active, closed
Boehringer Ingelheim
Phase 3
8,371
Alabama, Arizona, California, Colorado, Florida, Georgia, Idaho, Illinois
2024-08-30
Active, closed
Sanofi
Phase 2
229
Arizona, California, Colorado, Florida, Idaho, Kansas, Massachusetts, Michigan
2024-08-29
Recruiting
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
NCT06582017Ovarian Cancer, Pancreas Cancer, Urothelial Carcinoma, Renal Cell Carcinoma
Nammi Therapeutics Inc
Phase 1
100
California, Colorado, Georgia, New York, Texas, Wisconsin
2024-08-28
Active, closed
Gilead Sciences
Phase 3
640
Arkansas, California, Colorado, Connecticut, Florida, Georgia, Illinois, Indiana
2024-08-28
Recruiting
CytomX Therapeutics
Phase 1
121
California, Colorado, Pennsylvania, Tennessee, Texas
2024-08-28
Recruiting
Prevail Therapeutics
Phase 1
124
Colorado, Connecticut, Florida, Illinois, Michigan, Pennsylvania, Texas
2024-08-27
Active, closed
Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy
NCT06449222Locally Advanced Breast Cancer, Triple Negative Breast Cancer, Metastatic Triple Negative Breast Cancers
BioNTech SE
Phase 2
83
California, Colorado, Connecticut, Illinois, Minnesota, New Jersey, New York, Tennessee
2024-08-26
Recruiting
Janssen Research & Development, LLC
Phase 2
210
California, Colorado, Connecticut, New York, North Carolina, Ohio, Virginia, Washington
2024-08-26
Active, closed
Regeneron Pharmaceuticals
Phase 4
120
California, Colorado, Florida, Idaho, Illinois, Kansas, Kentucky, Maine
2024-08-26
Active, closed
Kodiak Sciences Inc
Phase 3
667
Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois, Indiana
2024-08-23
Recruiting
7 Hills Pharma, LLC
Phase 1/2
126
Colorado, Florida, New Hampshire, Rhode Island, Texas
2024-08-23
Active, closed
Kite, A Gilead Company
Phase 3
452
Arizona, California, Colorado, Florida, Georgia, Idaho, Illinois, Indiana
2024-08-23
Recruiting
Acepodia Biotech, Inc.
Phase 1
30
California, Colorado, Tennessee, Texas
2024-08-22
Active, closed
A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors
NCT06533059Cancer, Breast Cancer, Endometrial Cancer, Metastatic Cancer
Alterome Therapeutics, Inc.
Phase 1
110
California, Colorado, Florida, Massachusetts, Missouri, Tennessee, Texas, Virginia
2024-08-22
Recruiting
Sanofi
Phase 3
160
Alabama, Arizona, California, Colorado, Connecticut, Florida, Illinois, Kansas
2024-08-21
Recruiting
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
NCT06395103B-cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma, Burkitt Lymphoma, Neuroblastoma
Merck Sharp & Dohme LLC
Phase 1/2
90
California, Colorado, Connecticut, Florida, Iowa, Massachusetts, Michigan, Missouri
2024-08-16
Active, closed
DexCom, Inc.
Not applicable
283
Colorado, Florida, Georgia, Indiana, Minnesota, Missouri, New York, North Carolina
2024-08-15
Active, closed
Uniquity One (UNI)
Phase 2
182
Alabama, Arizona, California, Colorado, Florida, Georgia, Idaho, Illinois
2024-08-14
Recruiting
Sumitomo Pharma America, Inc.
Phase 1/2
120
California, Colorado, Florida, Illinois, Ohio, Tennessee, Texas, Washington
2024-08-14
Active, closed
Hoffmann-La Roche
Phase 4
19
Arkansas, California, Colorado, Florida, Georgia, Michigan, Texas
2024-08-14
Recruiting
Jazz Pharmaceuticals
Phase 3
550
Arizona, California, Colorado, District of Columbia, Florida, Massachusetts, Minnesota, Missouri
2024-08-13
Active, closed
Genentech, Inc.
Phase 2
118
Arkansas, Colorado, Florida, Indiana, Iowa, Maryland, Massachusetts, Nebraska
2024-08-09
Active, closed
AbbVie
Phase 3
111
California, Colorado, Connecticut, Illinois, Indiana, Massachusetts, Minnesota, New York
2024-08-08
Active, closed
EyeBiotech Ltd.
Phase 2/3
984
Arizona, Arkansas, California, Colorado, Connecticut, Florida, Illinois, Iowa
2024-08-07
Recruiting
Regeneron Pharmaceuticals
Phase 1/2
220
California, Colorado, Massachusetts, Michigan, New York, Ohio, Tennessee, Texas
2024-08-07
Recruiting
AstraZeneca
Phase 3
1,018
Alabama, Alaska, Arizona, California, Colorado, Connecticut, Delaware, Florida
2024-08-07
Active, closed
VTP-1000 in Adults With Celiac Disease
NCT06310291Celiac Disease
Barinthus Biotherapeutics
Early Phase 1
42
California, Colorado, Florida, Maryland, Michigan, Minnesota, New York, North Carolina
2024-08-01
Recruiting
Axsome Therapeutics, Inc.
Phase 3
520
Alabama, Arizona, Arkansas, California, Colorado, Florida, Georgia, Illinois
2024-08-01
By invitation
Viatris Innovation GmbH
Phase 3
680
Colorado, Florida, Louisiana, Nevada, Texas
2024-07-30
By invitation
Biohaven Therapeutics Ltd.
Phase 2
660
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia
2024-07-30
Active, closed
Annexon, Inc.
Phase 3
659
Arizona, California, Colorado, Florida, Georgia, Hawaii, Illinois, Iowa
2024-07-30
Active, closed
Avidity Biosciences, Inc.
Phase 2
84
California, Colorado, Florida, Georgia, Kansas, New York, North Carolina, Ohio
2024-07-25
Recruiting
Janssen Research & Development, LLC
Phase 3
752
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia
2024-07-25
Active, closed
Regeneron Pharmaceuticals
Phase 3
1,126
California, Colorado, Connecticut, Florida, Georgia, Hawaii, Illinois, Maryland
2024-07-24
Recruiting
Jacobio Pharmaceuticals Co., Ltd.
Phase 1/2
144
Colorado, Florida, Missouri, Ohio, Tennessee, Texas
2024-07-24
Active, closed
OncoVerity, Inc.
Phase 2
140
Arizona, California, Colorado, Connecticut, Florida, Iowa, Kentucky, New Jersey
2024-07-22
Recruiting
TG Therapeutics, Inc.
Observational
2,000
Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2024-07-22
Recruiting
Jazz Pharmaceuticals
Phase 3
286
California, Colorado, Florida, Georgia, Kansas, Kentucky, Louisiana, Massachusetts
2024-07-19
Active, closed
Celldex Therapeutics
Phase 3
976
Alabama, Arizona, California, Colorado, Florida, Georgia, Idaho, Illinois
2024-07-19
Recruiting
QUELIMMUNE (SCD-PED) PediAtric SurVeillance REgistry
NCT06517810Acute Kidney Injury, Acute Kidney Injury Due to Sepsis
SeaStar Medical
Observational
50
Alabama, California, Colorado, Georgia, Illinois, Michigan, Ohio, Pennsylvania
2024-07-19
Recruiting
Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.
NCT06590857Metastatic Breast Cancer, HER2-negative Breast Cancer, ER+ Breast Cancer, Advanced Breast Cancer
DrugRYZ101
RayzeBio, Inc.
Phase 1/2
64
Arizona, California, Colorado, Florida, Georgia, Indiana, Massachusetts, Michigan
2024-07-19
Recruiting
A Study of NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1)
NCT06521554Locally Advanced Solid Tumor, Metastatic Solid Tumor
Nuvalent Inc.
Phase 1
200
California, Colorado, District of Columbia, Florida, Maryland, Massachusetts, Michigan, Missouri
2024-07-18
Recruiting
Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)
Phase 2
385
California, Colorado, Florida, Georgia, Louisiana, Missouri, Nevada, North Carolina
2024-07-18
Active, closed
Merck Sharp & Dohme LLC
Phase 3
300
Arizona, California, Colorado, Connecticut, Indiana, Michigan, Nevada, North Carolina
2024-07-16
Active, closed
Zydus Therapeutics Inc.
Phase 3
102
California, Colorado, Connecticut, Florida, Georgia, Indiana, New York, North Carolina
2024-07-16
Active, closed
A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Not Work
NCT06290128Chronic Inflammatory Demyelinating Polyradiculoneuropathy, Polyneuropathy, Inflammatory Demyelinating, Chronic
Sanofi
Phase 3
109
Alabama, California, Colorado, Connecticut, Florida, Illinois, Kansas, Louisiana
2024-07-12
Recruiting
Replimune, Inc.
Phase 3
400
Arizona, California, Colorado, District of Columbia, Florida, Georgia, Illinois, Iowa
2024-07-11
Active, closed
Celldex Therapeutics
Phase 3
963
Alabama, California, Colorado, Florida, Idaho, Illinois, Indiana, Kentucky
2024-07-11
Recruiting
A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors
NCT06515613Platinum-resistant Ovarian Cancer, Testicular Cancer, Endometrial Cancer
Context Therapeutics Inc.
Phase 1
156
Arkansas, California, Colorado, Massachusetts, Nebraska, New Jersey, New York, North Carolina
2024-07-10
Recruiting
Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 or 2 Systemic Treatment Regimens
NCT06127407Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen
Servier Bio-Innovation LLC
Phase 3
156
California, Colorado, Connecticut, Florida, Georgia, Illinois, Iowa, Maryland
2024-07-09
Active, closed
Mesoblast, Ltd.
Phase 3
300
Arizona, California, Colorado, Florida, Georgia, Hawaii, Kansas, Kentucky
2024-07-03
By invitation
Apnimed
Phase 3
1,280
Alabama, Arizona, Arkansas, California, Colorado, Florida, Georgia, Idaho
2024-07-03
Recruiting
Study of WAL0921 in Patients With Glomerular Kidney Diseases
NCT06466135Diabetic Nephropathies, Primary Focal Segmental Glomerulosclerosis, Minimal Change Disease, Primary Immunoglobulin A Nephropathy
Walden Biosciences
Phase 2
96
California, Colorado, Florida, Georgia, Illinois, South Dakota, Texas
2024-07-02
Recruiting
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
NCT06465069Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm
Eli Lilly and Company
Phase 1
460
California, Colorado, Florida, Georgia, Illinois, Indiana, Massachusetts, Michigan
2024-07-01
Active, closed
AstraZeneca
Phase 3
339
Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Illinois, Indiana
2024-06-29
Recruiting
Panafina, Inc.
Phase 2
36
Arkansas, California, Colorado, Florida, Illinois, Indiana, Maryland, Michigan
2024-06-28
Active, closed
Biosense Webster, Inc.
Not applicable
354
Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois, Maryland
2024-06-28
Recruiting
Global Paradise System US Post Approval Study
NCT06297291Hypertension, Cardiovascular Diseases, Vascular Diseases
ReCor Medical, Inc.
Observational
1,000
California, Colorado, Connecticut, Florida, Georgia, Idaho, Illinois, Kansas
2024-06-28
Active, closed
Pfizer
Phase 1
64
Arkansas, California, Colorado, District of Columbia, Michigan, Missouri, North Carolina, Ohio
2024-06-27
Recruiting
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Phase 3
264
Arizona, Colorado, Connecticut, District of Columbia, Florida, Kansas, North Carolina, Ohio
2024-06-25
Active, closed
Novo Nordisk A/S
Phase 3
10,000
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, District of Columbia
2024-06-25
Active, closed
Genmab
Phase 3
621
Alabama, Arizona, California, Colorado, District of Columbia, Florida, Georgia, Illinois
2024-06-25
Recruiting
SpliSense Ltd.
Phase 2
64
California, Colorado, Florida, Illinois, Massachusetts, Minnesota, New York, North Carolina
2024-06-24
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,530
Alabama, Arizona, California, Colorado, Connecticut, Delaware, Florida, Georgia
2024-06-24
Recruiting
Avistone Biotechnology Co., Ltd.
Phase 1
63
California, Colorado, Florida, Michigan, New York, Texas, Virginia, Washington
2024-06-24
Active, closed
Sanofi
Phase 2
185
Alabama, Arizona, California, Colorado, Connecticut, Florida, Indiana, Massachusetts
2024-06-20
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
220
California, Colorado, District of Columbia, Florida, Georgia, New York, Texas, Virginia
2024-06-20
Recruiting
Allogene Therapeutics
Phase 2
250
Arizona, Arkansas, California, Colorado, Delaware, District of Columbia, Florida, Georgia
2024-06-18
By invitation
A Long-Term Follow-Up Study of Participants With Sickle Cell Disease or Transfusion Dependent β-Thalassemia Who Received EDIT-301
NCT06363760Sickle Cell Disease, Transfusion-dependent Beta-Thalassemia, Hemoglobinopathies
Editas Medicine, Inc.
Observational
54
California, Colorado, Connecticut, Florida, Georgia, Minnesota, New York, North Carolina
2024-06-17
Active, closed
vTv Therapeutics
Phase 3
150
Arizona, Arkansas, California, Colorado, Florida, Georgia, Indiana, Iowa
2024-06-14
Recruiting
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
NCT06239194Biliary Tract Cancer, Breast Cancer, Cervical Cancer, Colon Cancer
ModeX Therapeutics, An OPKO Health Company
Phase 1/2
330
Colorado, Florida, Massachusetts, Tennessee, Texas
2024-06-12
Active, closed
AskBio Inc
Phase 2
59
Arizona, California, Colorado, District of Columbia, Florida, Georgia, Illinois, Kansas
2024-06-11
Recruiting
Transdermal Compress IDE Study
NCT06134167Prosthesis and Implants
Balmoral Medical company
Not applicable
100
California, Colorado, Illinois, Maryland, New York, Ohio, Pennsylvania
2024-06-11
Active, closed
Natera, Inc.
Not applicable
250
California, Colorado, Florida, Kansas, Massachusetts, Michigan, New York, North Carolina
2024-06-10
Recruiting
Merck Sharp & Dohme LLC
Phase 3
851
Arkansas, California, Colorado, District of Columbia, Florida, Georgia, Illinois, Michigan
2024-06-10
Recruiting
Exact Sciences Corporation
Observational
1,800
Alaska, California, Colorado, Florida, Illinois, Indiana, Kansas, Kentucky
2024-06-07
Active, closed
Janssen Research & Development, LLC
Phase 1
108
Arizona, Colorado, Florida, Georgia, Indiana, Ohio, Texas
2024-06-07
Recruiting
Immunocore Ltd
Phase 3
680
Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Illinois, Kansas
2024-06-05
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,200
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida
2024-06-05
Recruiting
QED Therapeutics, a BridgeBio company
Observational
150
California, Colorado, District of Columbia, Maryland, Missouri, Ohio, Tennessee, Wisconsin
2024-06-05
Recruiting
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1/2
252
Colorado, Connecticut, Florida, Kentucky, Missouri, Nevada, New Mexico, Oklahoma
2024-06-04
Active, closed
Kumquat Biosciences Inc.
Phase 1
92
Colorado, Florida, Michigan, New York, Ohio, Tennessee, Texas, Virginia
2024-06-03
Recruiting
Kartos Therapeutics, Inc.
Phase 3
600
Alabama, Arizona, California, Colorado, Delaware, District of Columbia, Florida, Iowa
2024-06-03
Active, closed
Hoffmann-La Roche
Phase 4
21
Arkansas, Colorado, Florida, Georgia, Texas
2024-05-30
Active, closed
Stealth BioTherapeutics Inc.
Phase 3
313
Arizona, California, Colorado, Connecticut, Florida, Illinois, Indiana, Maryland
2024-05-30
Active, closed
Janssen Research & Development, LLC
Phase 2
333
California, Colorado, Florida, Idaho, Illinois, Iowa, Minnesota, Missouri
2024-05-30
Rows per page Showing 501–1000 of 2073
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 22 November 2026. https://priyalifescience.com/clinical-trials-usa/state/colorado?page=2

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,148 studies in total at the last sync on 22 Nov 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 2,073 of those studies with a site in Colorado.

How many clinical trials are recruiting in Colorado?

1,031 of the 2,073 studies on this page are recruiting new participants as of the 22 Nov 2026, 03:16 UTC sync. A further 25 have not yet opened recruitment, 949 are active but closed to new participants, and 68 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.